СПОСОБ ПРОВЕДЕНИЯ ОФТАЛЬМОХИРУРГИЧЕСКИХ ОПЕРАЦИЙ С ИСПОЛЬЗОВАНИЕМ АУТОТРАНСПЛАНТАТА

Изобретение относится к медицине, а именно к офтальмологии. Способ включает выполнение воспринимающего ложа и имплантацию в него по меньшей мере одного трансплантата. В качестве материала для изготовления трансплантата используют фрагмент ногтевой пластинки самого пациента, который моделируют по форме воспринимающего ложа, а после стерилизации перед имплантацией трансплантат выдерживают в сухой атмосфере. Способ обеспечивает адаптацию трансплантата к форме воспринимающего ложа в результате естественного разбухания и использования аутотрансплантата, близкого по своему химическому составу и физическим свойствам к тканям глаза. 9 з.п. ф-лы, 1 ил., 4 пр.

СПОСОБ ПОЛУЧЕНИЯ СМЕСИ ДЛЯ РАСПЫЛЕНИЯ КЛЕТОК-ФИБРОБЛАСТОВ КЕРАТИНОЦИТОВ ЧЕЛОВЕКА В РАСТВОРЕ И ЕЕ ПРИМЕНЕНИЕ В КАЧЕСТВЕ РЕГЕНЕРАТИВНОГО АГЕНТА ПРИ ПОВРЕЖДЕНИЯХ КОЖИ

PROCEDURE FOR THE PROCESSING AND PRESERVATION FROM FABRIC PARTS BASED ON KOLLAGEN TO THE TRANSPLANT

Composite medical grafts and methods of use and manufacture

Provided in this disclosure are various composite grafts having a trabecular scaffold with voids defined in at least a portion of the scaffold and a biological component positioned in at least some of the voids of the scaffold. The grafts may have a synthetic scaffold or a bone substrate scaffold. The grafts may be osteogenic, chondrogenic, osteochondrogenic, or vulnerary in nature. Also provided are methods of using the composite grafts to treat a tissue defect in a subject. Methods of manufacturing are also provided. Synthetic scaffolds are manufactured by additive manufacturing. Agitation is used to combine the biological component with the scaffold of the graft.

Skin-augmenting surgical sutures

The present invention relates to surgical sutures and threads for introducing skin-augmenting materials into human tissues, such as the skin.

Tissue matrices incorporating multiple tissue types

The present disclosure provides tissue products produced from extracellular tissue matrices. The tissue products can include acellular extracellular matrices including combinations of different tissue types. The combination can harness various properties of the different tissues to provide improved composite structures with desired mechanical and/or biologic properties.

Breast treatment device

The present disclosure provides devices for treating breasts. The devices (100) include a sheet of acellular tissue matrix having a predefined shape that allows for complete or enhanced coverage of an anterior portion of a breast implant or tissue expander or to support an implant and/or surrounding tissues. The sheet includes curved upper and lower borders or edges.

Sheet-like decellularized material and artificial blood vessel employing said material

The present invention relates to a sheet-like decellularized material of biological material origin, wherein the maximum value of the tensile strengths in four directions is equal to or greater than 4 MPa, and the expansion rate in the direction in which the tensile strength reaches the maximum is 50% to 300%. The present invention provides a sheet-like material that is capable of maintaining a superior pressure resistance when used as a blood vessel or when used to repair a blood vessel.

Method of treating or preventing hernia formation

A method of preventing or reducing the occurrence and/or development of a hernia within a subject at risk of developing a hernia includes implanting a graft material in contact with an opening in an abdominal wall. The graft material promotes healing of the abdominal wall and includes placental or placental derived tissue.

Producing a transplant from animal dermis using sodium sulfide solution

The invention relates to a method for producing a transplant from animal dermis, in particular from porcine dermis, comprising the following steps: a) providing animal dermis, b) treating the animal dermis with an aqueous solution containing sodium sulfide, c) treating the dermis with an aqueous salt solution once or several times, d) possibly treating the dermis with an aqueous hydrogen peroxide solution once or several times, and e) dehydrating the dermis. The invention further relates to a transplant that can be obtained by means of the aforementioned method.

Elongated tissue matrices

Elongated and high aspect ratio tissue treatment products are provided. Methods of making and using the tissue treatment products are also provided. The tissue treatment products can be used as implants that conform to the site of implantation and resist migration away from their implantation site in vivo.

Functionalized tissue matrices

Disclosed herein are tissue treatment products that have been bound to at least one chelating agent. Also disclosed are tissue treatment products that have been functionalized with at least one metal and/or at least one metal-binding protein. The tissue treatment products can have antimicrobial properties and/or factors that promote or enhance native ceil migration, proliferation, and/or revascularization after implantation into a subject. Also disclosed are methods of making and using the tissue treatment products. The tissue treatment products can be implanted into a tissue in need of repair, regeneration, healing, treatment, and/or alteration and can promote or enhance native cell migration, proliferation, and/or revascularization.

Functionalized tissue matrices

Disclosed herein are tissue treatment products that have been bound to at least one chelating agent. Also disclosed are tissue treatment products that have been functionalized with at least one metal and/or at least one metal-binding protein. The tissue treatment products can have antimicrobial properties and/or factors that promote or enhance native ceil migration, proliferation, and/or revascularization after implantation into a subject. Also disclosed are methods of making and using the tissue treatment products. The tissue treatment products can be implanted into a tissue in need of repair, regeneration, healing, treatment, and/or alteration and can promote or enhance native cell migration, proliferation, and/or revascularization.

Method for enzymatic treatment of tissue products

Methods for treating tissue matrices and tissue matrices produced according to the methods are provided. The methods can include treating a tissue matrix with a proteolytic enzyme to produce a desired pliability of the tissue matrix.

Method for processing and preserving collagen-based tissues for transplantation

METHOD FOR PROCESSING TISSUES

Methods for processing tissue are provided. In some embodiments, the methods comprise methods for decellularizing tissue samples by applying high hydrostatic pressure to the tissues samples. In some embodiments, the methods comprise methods for thawing tissue samples and/or reducing the bioburden in a sample by applying high hydrostatic pressure to the tissue samples.

REINFORCED TISSUE MATRICES

Devices, methods of producing devices, and methods of treating an anatomic defect are provided. The devices and methods can include a flexible sheet of acellular tissue matrix and one or more elongated synthetic elements. The one or more synthetic elements may extend through the flexible sheet such that the one or more synthetic elements extend substantially parallel to a first top surface and a second bottom surface within one or more portions of the flexible sheet, and may be exposed on one or more portions of the first top surface of the device.

TISSUE PRODUCTS WITH VARIATIONS IN MECHANICAL PROPERTIES AND METHODS OF TREATMENT

Devices with improved biomechanical properties and methods for treating tissue are provided. The compositions may comprise a cellular tissue matrices specifically shaped and sized for facial and neck implantation and having variations in mechanical and/or biological properties. Also provided are methods for treating tissue using these devices.

DERIVATION OF HUMAN SKIN ORGANOIDS FROM PLURIPOTENT STEM CELLS

Provided herein are methods for directing differentiation of human pluripotent stem cells into a three-dimensional multilayered skin composition comprising an epidermal layer, a dermal layer, and a plurality of cells capable of forming a functional hair follicle. Also provided herein are three-dimensional, multilayered engineered skin compositions and methods of using the same for drug screening, for screening compounds for effects on hair growth, and for other applications.

TISSUE MATRIX WITH PREFORMED OPENINGS OR PILOT OPENINGS

The present disclosure relates to tissue matrix products. The products can include tissue matrices that have openings such as holes or perforations located at certain positions to improve various functions without substantial loss of strength or other important properties. The openings can facilitate implantation of the tissue matrices in surgical procedures thereby speeding operation times and potentially improving surgical results.

INJECTABLE POLYURETHANES AND APPLICATIONS THEREOF

Polyurethane-based tissue fillers useful for treating and/or augmenting tissue, as well as acting as a biological scaffold that promotes cell in-ingrowth and tissue integration, are disclosed, as are quick-setting, injectable precursors of such tissue fillers. Such tissue fillers generally comprise (1 ) a polyurethane and (2) a particulate acellular tissue matrix. Also disclosed are methods of treating and/or augmenting tissues using such tissue fillers, particularly voids in human tissue such as anal fistulae or hernias.

SURGICAL METHODS/DEVICES FOR TISSUE INJURY REMOVAL BY TATTOOING OF AUTOLOGOUS STEM CELLS

A method and a device for autografting of fat microparticles containing stem cells of various types, injected into scars, or stretch marks, and/or other cutaneous injuries, at epidermis-dermis level is presented. Fat is taken from the patient in the periumbilical area, where large quantities of mesenchymal stem cells exist. After reduction in size by means of a thin grid emulsifier filter the fat microparticles are loaded into a tank of a multi-needle gun, such as used for tattoos. The multi-needle tattoo gun injects the fractionated fat microparticles into the epidermis-dermis of scars, and/or stretch marks and/or other skin defects or even internal injuries. The injected fat particles trigger tissue regeneration, deleting scars. stretch marks, wrinkles and/or other defects or skin damages in 3-4 weeks. This method for regeneration of tissues can be extended to all surgeries. including vital organs of the human body; always by means of tattooing the target organ with autologous fat microparticles ...

CELL REPOPULATED COLLAGEN MATRIX FOR SOFT TISSUE REPAIR AND REGENERATION

The present invention provides compositions for treating soft tissue injuries comprising a collagen matrix and mesenchymal stem cells adhered to the collagen matrix. Methods of making and using compositions comprising a collagen matrix and mesenchymal stem cells adhered to the collagen matrix are also provided.

METHODS OF REMOVING ALPHA-GALACTOSE

Tissue products lacking a desired percentage of immunogenic epitopes, such as galactose alpha-1,3 galactose epitopes, are provided. Methods of making and using the tissue products are also provided.

COLLAGEN SPONGE

A resilient resorbable chemically crosslinked collagen sponge for promoting soft tissue volume augmentation in the oral region, comprising 60-96 % (w/w) collagen and 4-40 % (w/w) elastin, which shows by mercury intrusion porosimetry interconnected pores with a median pore diameter between 50 and 90 µI.tau.I and at least 80 % porosity with a pore diameter more than 10 µI.eta.; an onset temperature of 45 to 57 °C and a density in dry state from 50 to 65 mg/cm3. -A process for preparing that resilient resorbable chemically crosslinked collagen sponge, and - That resilient resorbable chemically crosslinked collagen sponge for use as an implant in the oral cavity for soft tissue volume augmentation.

METHODS OF DRYING SHEETS OF TISSUE

Embodiments of the technology may involve a method of processing the human donor tissue for administration to a recipient. This method may include the step of contacting the human donor tissue with a backing layer, where the human donor tissue and the backing layer contain a saline solution. This saline solution may include a solvent and a disassociated salt. The method may further include evaporating a portion of the solvent from a surface of the backing layer. The evaporation of the solvent may move a portion of the disassociated salt from the donor tissue to the backing layer. This process may then result in a tissue that is mostly dry and free of salt crystals.

ELONGATED TISSUE MATRICES

Elongated and high aspect ratio tissue treatment products are provided. Methods of making and using the tissue treatment products are also provided. The tissue treatment products can be used as implants that conform to the site of implantation and resist migration away from their implantation site in vivo.

METHOD OF PRODUCING SUSPENZIONNNOI SHAPE GROUND DETsELLYuLYaRIZOVANNOGO EXTRACELLULAR MATRIX

Procédé d'obtention de fibres de collagène de peau d'origine humaine, fibres ainsi obtenues et composition les contenant

L'invention concerne un procédé d'obtention de fibres de collagène obtenues à partir de fragments de peau humaine. On traite le matériau de départ pour obtenir, par action d'une solution de chlorure de magnésium, une suspension de fibrilles de collagène; on reforme in vitro les fibres de collagène sous l'action d'un promoteur de fibrillogénèse constitué par un sel d'acide de la glucosamine et/ou l'acide N-acétyl neuraminique; on contrôle en microscopie les fibres obtenues et, si nécessaire, on les lave par une solution de sorbitan; on rince les fibres et on les utilise dans une composition tamponnée pour des injections dermiques sur le sujet qui a fourni les fragments de peau servant de matériau de départ.

A method of manufacturing bone graft materials with a hole

Tissue scaffolds

Tissue scaffolds are described herein. Also described are devices for treating wounds and methods of treating wounds using tissue scaffolds.

Materiales y métodos para protegerse contra los neuromas (divisional de la solicitud 201903073)

La presente invención proporciona dispositivos y métodos para aliviar las molestias asociadas con la formación de neuromas. Los dispositivos y métodos de la invención utilizan de manera efectiva la respuesta natural del cuerpo de reconstruir biomateriales implantados para minimizar el tamaño, aislar y proteger un neuroma. En modalidades preferidas, el dispositivo es una tapa cilíndrica, en la que la cámara interna de la tapa cilíndrica divide físicamente el nervio para permitir una disposición de las fibras nerviosas (a diferencia de las fibras nerviosas dispuestas al azar a menudo en neuromas). Las pestañas dispuestas en el exterior de la tapa se pueden usar para manipular la tapa en un nervio. El extremo abierto también se puede configurar con aletas que se pueden usar para ensanchar el extremo abierto para facilitar la inserción del nervio en la tapa. Además, el material de la tapa se remodela en un cojín de tejido después de la implantación, lo que protege al neuroma de ser estimulado ...

NANOFIBER SCAFFOLDS AND METHODS FOR REPAIRING SKIN DAMAGE

A composition is provided that includes a plurality of layered nanofiber scaffolds. A first nanofiber scaffold can include microwells configured to be seeded with one or more relevant cells, a skin tissue, or combinations thereof. Furthermore, the first nanofiber scaffold can comprise uniaxially aligned nanofibers between the microwells and random nanofibers on the microwells. The composite can also include a second nanofiber scaffold that comprises radially-aligned nanofibers. Further provided are methods for making such a composition as well as methods for treating damaged skin that include applying an effective amount of the composition to a site of damaged skin on a subject.

Tissue regenerative composition, method of making, and method of use thereof

A matrix, including epithelial basement membrane, for inducing repair of cmammalian tissue defects and in vitro cell propagation derived from epithelial tissues of a warm-blooded vertebrate.

Graft materials for surgical breast procedures

Graft materials and devices for surgical breast procedures may include a sheet of biocompatible material and a plurality of fenestrations distributed across a portion of the sheet of biocompatible material. The sheet of biocompatible material can have a first axis and a second axis coincident with the sheet of biocompatible material. The sheet of biocompatible material can also have a first edge that intersects the second axis and a second edge that intersects the second axis. The first axis can be orthogonal to the second axis. The plurality of fenestrations can be distributed across a portion of the sheet of biocompatible material closer to the first edge than the second edge. Other apparatuses and methods are disclosed.

TISSUE REPAIR MATERIAL DERIVED FROM FISH SKIN AND MANUFACTURING METHOD THEREOF

A tissue repair material derived from fish skin and manufacturing method thereof is applied to provide the tissue repair material suitable for use as a patch, a cover, a carrier, a scaffold, an implant or a reagent in various tissues. The tissue repair material has collagens to improve the wounded tissue repair, and has particular characters for desired tissue repair application. Furthermore, so far the factors of the terrestrial animal transmitted disease (caused by virus) do not survive on the tissue repair material derived from fish skin.

Graft materials for surgical breast procedures

Graft materials and devices for surgical breast procedures, as well as methods of making graft devices are described.

FLOWABLE TISSUE PRODUCTS

The present disclosure provides tissue fillers. The tissue fillers can include a plurality of tissue particles formed from acellular tissue matrix fragments. The tissue fillers can be used to fill tissue sites, such as voids formed after tissue resection.

TEMPORARY SPACE-FILLING PENILE IMPLANT FOR CORPORAL HEALING AND NEOPHALLUS CONDITIONING

A temporary space-filling penile implant device for penile surgery includes a body portion, an end portion attached to the body portion, and a cover surrounding the end portion and at least a portion of the body portion. The temporary space-filling penile implant may be configured for insertion into either corpora cavernosa of a penis or into interior tissue of a neophallus, during an inter-procedure time period that occurs between two surgical procedures performed on the penis or the neophallus.

ИСКУССТВЕННАЯ КОЖА

Группа изобретений относится к медицине, а именно к способу получения искусственной кожи. Способ получения искусственной кожи, включающей эпидермальную базальную мембрану, содержащую непрерывную темную пластинку (lamina densa) и якорные волокна, исходящие из lamina densa, и дерму, содержащую коллагеновые волокна, предусматривающий добавление ингибитора матриксной металлопротеиназы и ингибитора гепараназы к культуральной среде для образования искусственной кожи, содержащей кератиноциты эпидермиса человека и фибробласты дермы человека; культивирование клеток в культуральной среде для образования искусственной кожи и образование искусственной кожи. Искусственная кожа. Агент, стимулирующий образование темной пластинки (lamina densa) и якорных волокон, связанных с темной пластинкой, содержащий ингибитор матриксной металлопротеиназы и ингибитор гепараназы. Агент, стимулирующий образование выпячиваний на поверхности клеточных мембран (fibripositors) и образование темной пластинки (lamina densa ...

УСТРОЙСТВО ДЛЯ КОРРЕКЦИИ МОЛОЧНОЙ ЖЕЛЕЗЫ

Группа изобретений относится к устройствам для коррекции молочных желез. Устройство для коррекции молочной железы содержит лист бесклеточной тканевой матрицы, содержащий гибкий лист с верхней поверхностью и нижней поверхностью. Лист имеет верхнюю изогнутую границу с первой степенью кривизны и нижнюю изогнутую границу со второй степенью кривизны. Верхняя изогнутая граница и нижняя изогнутая граница соединены в верхних точках боковых концов устройства, разделенных расстоянием от 15 до 30 см. Верхняя изогнутая граница и нижняя изогнутая граница определяют высоту по меньшей мере 15 см для более полного покрытия имплантата молочной железы. Форма и размер нижней изогнутой границы соответствует форме нижнего края молочной железы. Раскрыт способ коррекции молочной железы, включающий использование устройства, содержащего лист бесклеточной тканевой матрицы и имплантацию устройства вместе с имплантатом молочной железы или тканевым экспандером в молочную железу. Технический результат состоит в снижении ...

СПОСОБ ПОЛУЧЕНИЯ СУСПЕНЗИОННОЙ ФОРМЫ ИЗМЕЛЬЧЕННОГО ДЕЦЕЛЛЮЛЯРИЗОВАННОГО ВНЕКЛЕТОЧНОГО МАТРИКСА

Изобретение относится к области фармацевтики и медицины, а именно к способу получения не требующей предварительной регидратации суспензионной формы измельченного децеллюляризованного внеклеточного матрикса с регулируемым размером его структурных компонентов, а также к продукту, полученному указанным способом, который предназначен для стимуляции репаративной регенерации тканей. Способ включает сепарирование пластов очищенного волонистого внеклеточного матрикса, измельчение пластов, фракционирование порошка и суспендирование отобранной фракции частиц очищенного внеклеточного матрикса в жидкой среде путем чередования циклов перемешивания и диспергирования частиц в жидкой среде с преобладанием по длительности процесса перемешивания при температуре, не вызывающей денатурацию коллагена, и дегазацию полученной суспензии частиц. Способ по изобретению обеспечивает получение суспензионной формы децеллюляризованного внеклеточного матрикса с регулируемым размером его структурных компонентов, применение ...

RESORBIERBARE IMPLANTATMATERIALIEN

Tissue scaffolds

Interfaced medical implant assembly

Rapid allograft treatment systems and methods

Provided are systems and methods for treating or processing tissue, and tissue products made using such systems and methods. The methods involve combining tissue with a processing solution in a processing vessel and applying resonant acoustic energy thereto. In some instances, the tissue is processed in the absence of processing solution. The resonant acoustic energy rapidly agitates the tissue with the processing solution by vibration. The general method provided is broadly applicable to a variety of tissue processing methods, the processing solution and features of the resonant acoustic energy being selected based on the type of tissue to be processed and the nature of the processing to be performed. Exemplary methods include methods of bone demineralization, tissue decellularization, tissue cryopreservation, production of stromal vascular fraction, tissue homogenization, tissue cleansing, and tissue decontamination, and assessment of microbial load. By applying resonant acoustic energy ...

Tissue products with active agents and methods of production

The present disclosure relates to methods for producing tissue matrix products with active agents to achieve localized distribution and controlled active agent release. The method can include inserting a carrier element comprising a biodegradable material and active agent into surface features of a tissue matrix product. Also provided are tissue matrix products made using the disclosed methods.

Regenerative materials

Methods of making tissue fillers are provided. In certain embodiments, the tissue is flake-like and has regenerative properties.

METHOD FOR PRODUCING A GRAFT, CUTTING DEVICE AND PUNCHING DEVICE FOR THE IMPLEMENTATION OF THE SAID METHOD

The invention relates to a method for producing a graft for a patient consisting of foreign skin provided with openings and segments of a piece of the patient's original skin inserted into the openings. A holding device for a piece of the patient's original skin is placed in a transfer device at a location defined by positioning means in a system of co-ordinates in which segments of the patient's original skin are also arranged at specific locations. A backing, carrying foreign skin, is placed at another location defined within the system of co-ordinates by additional positioning means, Openings are cut into the foreign skin at similarly defined locations. A transporting device is placed on each segment of the patient's original skin, the transporting device comprising means which, upon being lifted, carry along the relevant segment of the patient's original skin and, upon being set down, release the segment of skin. Also provided is a manipulator which moves the transporting parts to the ...

METHOD OF TREATING OR PREVENTING HERNIA FORMATION

A method of preventing or reducing the occurrence and/or development of a hernia within a subject at risk of developing a hernia includes implanting a graft material in contact with an opening in an abdominal wall. The graft material promotes healing of the abdominal wall and includes placental or placental derived tissue.

SOFT TISSUE REPAIR GRAFTS AND PROCESSES FOR PREPARING AND USING SAME

Soft tissue repair grafts are provided for supporting, covering, and/or retaining an implant positioned in the body of a subject. The grafts are particularly suitable for use for pre-pectoral breast reconstruction with a breast implant or tissue expander. The grafts include positional notches for more accurate positioning in a subject. The grafts also include at least one cuff element which is folded to form a reinforced folded edge for suturing the graft more securely to adjacent tissues than previously known grafts. The grafts also include a plurality of arcuate slots which form a plurality of circular patterns arranged concentrically about a focal point, thereby enabling the grafts to expand without tearing and to conform more closely to the implant and/or adjacent body tissues such as the breast pocket, than previously known grafts. Acellular dermal matrices are particularly suitable for making the soft tissue repair grafts.

SOFT TISSUE REPAIR GRAFTS AND PROCESSES FOR PREPARING AND USING SAME

Soft tissue repair grafts are provided for supporting, covering, and/or retaining an implant positioned in the body of a subject. The grafts are particularly suitable for use for pre-pectoral breast reconstruction with a breast implant or tissue expander. The grafts include positional notches for more accurate positioning in a subject. The grafts also include at least one cuff element which is folded to form a reinforced folded edge for suturing the graft more securely to adjacent tissues than previously known grafts. The grafts also include a plurality of arcuate slots which form a plurality of circular patterns arranged concentrically about a focal point, thereby enabling the grafts to expand without tearing and to conform more closely to the implant and/or adjacent body tissues such as the breast pocket, than previously known grafts. Acellular dermal matrices are particularly suitable for making the soft tissue repair grafts.

PIXEL ARRAY MEDICAL SYSTEMS, DEVICES AND METHODS

Systems, instruments, methods, and compositions are described involving removing a portion of the epidermis within a donor site on a subject, and harvesting dermal plugs within the donor site. An injectable filler is formed by mincing the dermal plugs. The injectable filler is configured for injecting into a recipient site on the subject.

METHODS FOR LOCALIZED MODIFICATION OF TISSUE PRODUCTS

Methods for treating tissue matrices and tissue matrices produced according to the methods are provided. The methods can include treating select portions of a tissue matrix with a fluid containing at least one agent to produce a tissue matrix with variable mechanical and/or biological properties ...

METHOD FOR PRODUCING A GRAFT, CUTTING DEVICE AND PUNCHING DEVICE FOR THE IMPLEMENTATION OF THE SAID METHOD

COMPOSITE MATERIAL FOR WOUND REPAIR

A composite (1) comprising a barrier material (2) and a support material (3) used for wound or tissue repair. Benefits include decreased adhesion to organs or other structures adjacent to the repair site, limited fluid flux, increased vascularization and cellular infiltration, decreased inflammation and reduced scar tissue formation.

MATRIX BOUND NANOVESICLES AND THEIR USE

A composition is disclosed herein that includes isolated ECM-derived nanovesicles and a pharmaceutically acceptable carrier. Methods are producing the ECM-derived nanovesicles are also disclosed. These ECM-derived nanovesicles can be included in pharmaceutical compositions, bioscaffolds, and devices. Methods for using these ECM-derived nanovesicles are provided.

ELASTASE TREATMENT OF TISSUE MATRICES

A method of producing a modified acellular tissue matrix (mATM) from an acellular tissue matrix (ATM), where the mATM has a reduced stretchiness relative to the ATM, without substantially compromising its associated structural or functional integrity. The method includes providing an acellular tissue matrix (ATM) and exposing the ATM to elastase for a period of time.

BIOLOGIC TREATMENT SYSTEM AND METHOD

A delivery system is provided that is adapted to treat various urological pelvic disorders, such as prolapse, incontinence, and the like. The delivery system can include at least one biologic loaded or otherwise provided with a bioactive agent. The biologic can comprise any drugs, hormones or steroids, stem cells, growth factors, proteins, and/or other bioactive agents to promote cell or tissue growth for the treatment and strengthening of organ walls or tissue. The biologic is generally adapted to controllably release the agent to the surrounding tissue or organ to provide a local and targeted delivery.

GRAFT MATERIALS FOR SURGICAL BREAST PROCEDURES

Graft materials and devices for surgical breast procedures, as well as methods of making graft devices are described. A medical device is disclosed comprising a sample of biocompatible material (13b) including a first edge (15b) and a second edge (17b). The first edge (15b) comprises a convex portion that curves away from the second edge and the second edge includes a portion that curves away from the first edge. The first and second edges are joined at an apex (19d-19e).

FLOWABLE TISSUE PRODUCTS

The present disclosure provides tissue fillers. The tissue fillers can include a plurality of tissue particles formed from acellular tissue matrix fragments. The tissue fillers can be used to fill tissue sites, such as voids formed after tissue resection.

METHOD FOR OBTAINING A SPRAY-ON CELLULAR COMPOUND OF HUMAN FIBROBLASTS AND KERATINOCYTES IN SOLUTION AND THE USE THEREOF AS A REGENERATIVE AGENT IN SKIN LESIONS

The invention relates to a process for obtaining a spray-on cellular compound of human fibroblasts and keratinocytes and to the use thereof as a regenerative agent in skin lesions, mostly diabetic ulcers and 1st, 2nd and 3rd degree burns, and as a substitute for flap surgery. The method for obtaining a spray-on cellular compound of human fibroblasts and keratinocytes comprises the steps of: isolating the dermis and epidermis, incubating the epidermal layer, disintegrating the dermal layer and proliferating the fibroblasts, disintegrating the epidermal layer, proliferating the keratinocytes in suspension, preparing the solution of crosslinking agent solution for reacting with the spray-on cellular solution and preparing the spray-on cellular solution. Said spray-on cellular compound of human fibroblasts and keratinocytes increases the effectiveness and ease of application, and is intended to be an economical, rapid and easy-to-use alternative.

MICROBIAL ENZYMES FOR REDUCTION OF ALPHA-GALACTOSE FROM COLLAGEN BASED TISSUE

Methods for preparing a non-human tissue matrix for transplantation are provided.

DOUBLE CROSS-LINKAGE PROCESS TO ENHANCE POST-IMPLANTATION BIOPROSTHETIC TISSUE DURABILITY

Bioprosthetic tissues and methods for making same, comprising fixing bioprosthetic implant tissue by treatment with 0.1 to 10 wt. % glutaraldehyde at elevated temperature, capping said fixed tissue by treatment with a diamine crosslinking agent, and treating said capped tissue with about 0.6 wt.% glutaraldehyde.

NONPOLYMERIC EPOXY COMPOUNDS FOR CROSS-LINKING BIOLOGICAL TISSUE AND BIOPROSTHETIC GRAFTS PREPARED THEREBY

Nonpolymeric epoxy compounds for cross-linking biological tissues and bioprosthetic materials prepared thereby. The nonpolymeric epoxy compounds of the present invention have the general structural formula: R1-CH2-O-X-O-CH2-R2 wherein, X is either (a) a straight chain aliphatic hydrocarbon having at least four (4) and no more than five (5) carbon atoms bonded directly to one another, said straight chain aliphatic hydrocarbon being devoid of side branches and having terminal carbon atoms at either end therof, the terminal carbon atoms at the ends of said straight chain aliphatic hydrocarbon being bonded to the oxygen atoms shown in the foregoing general formula, (b) a substituted aromatic hydrocarbon, or (c) a substituted or unsubstituted cycloaliphatic hydrocarbon; and, wherein at least one of the terminal groups R1, or R2 is an epoxy group and the other of said terminal groups R1 or R2 is either (a) an epoxy group, (b) an aldehyde group, (c) an isocyanate group, or (d) a thiocyanate group ...

Method for preparing animal acellular tissue matrix material and tissue matrix material prepared by same

Hair follicle graft from tissue engineered skin

The present invention provides a hair graft comprising (a) tissue engineered skin comprising a tissue engineered epidermal layer, a tissue engineered dermal layer, and hair follicle progenitor cells and (b) a scaffold. The invention also provides methods of making and using the hair grafts of the present invention.

METHOD FOR PROCESSING TISSUES

Methods for processing tissue are provided. In some embodiments, the methods comprise methods for decellularizing tissue samples by applying high hydrostatic pressure to the tissues samples. In some embodiments, the methods comprise methods for thawing tissue samples and/or reducing the bioburden in a sample by applying high hydrostatic pressure to the tissue samples.

NONPOLYMERIC EPOXY COMPOUNDS FOR CROSS-LINKING BIOLOGICAL TISSUE AND BIOPROSTHETIC GRAFTS PREPARED THEREBY

Nonpolymeric epoxy compounds for cross-linking biological tissues and bioprosthetic materials prepared thereby. The nonpolymeric epoxy compounds of the present invention have the general structural formula: R1-CH2-O-X-O-CH2-R2 wherein, X is either (a) a straight chain aliphatic hydrocarbon having at least four (4) and no more than five (5) carbon atoms bonded directly to one another, said straight chain aliphatic hydrocarbon being devoid of side branches and having terminal carbon atoms at either end therof, the terminal carbon atoms at the ends of said straight chain aliphatic hydrocarbon being bonded to the oxygen atoms shown in the foregoing general formula, (b) a substituted aromatic hydrocarbon, or (c) a substituted or unsubstituted cycloaliphatic hydrocarbon; and, wherein at least one of the terminal groups R1, or R2 is an epoxy group and the other of said terminal groups R1 or R2 is either (a) an epoxy group, (b) an aldehyde group, (c) an isocyanate group, or (d) a thiocyanate group ...

Tissue regenerative composition, method of making, and method of use thereof

A matrix, including epithelial basement membrane, for inducing repair of mammalian tissue defects and in vitro cell propagation derived from epithelial tissues of a warm-blooded vertebrate.

Resorbable implant materials

A non-crosslinked, decellularized and purified mammalian tissue (e.g., bovine pericardium) having particular use as an implantable resorbable material. The material is treated by alkylating its primary amine groups in a manner sufficient to reduce the antigenicity of the tissue, permitting the treated tissue to be used in vivo and without crosslinking, and in turn, permitting it to be resorbable. The material can be used in surgical repair of soft tissue deficiencies for a certain period of time while the implant itself is gradually remodeled or absorbed by the host. Also provided are a method of preparing such a material, as well as a method of using such a material for surgical repair.

Regenerative materials

Methods of making tissue fillers are provided. In certain embodiments, the tissue is flake-like and has regenerative properties.

Mesh or membrane covering based on biological or biosynthetic material for prosthesis, provided with fixing system for fixing to the same prosthesis, and corresponding manufacturing process thereof

The present invention relates to a mesh or membrane covering (2) based on biological material, for example collagen, or biosynthetic material for prostheses (1), in particular for a breast prosthesis (1), said prosthesis (1) having a rear surface that, when applied, is faced towards the person on whom (1) is applied, said covering (2) being characterized in that it provides a fixing system (4; 3) for fixing to said prosthesis (1), said fixing system providing a plurality of teeth or petals (4) or outer perimeter edge foldable on said rear surface of the prosthesis (1) by means (5). The invention further relates to a method for fixing said covering to a prosthesis, a prosthesis comprising said covering and a process for making said covering.

СПОСОБ ВОССТАНОВЛЕНИЯ СВЯЗКИ ИЛИ СУХОЖИЛИЯ

Изобретение относится к медицине, а именно к травматологии, и может быть использовано для восстановления у пациента связки или сухожилия. Для этого на связку или сухожилие накладывают лоскут, который является гибким и биосовместимым и содержит опорный слой, состоящий из листового коллагена и являющийся проницаемым для клеток, а также расположенный на опорном слое матриксный слой, проницаемый для клеток и представляющий собой коллагеновую прокладку с распределенными в ней коллагеновыми волокнами и природной гиалуроновой кислотой, диспергированной в свободных пространствах коллагеновых волокон. Способ обеспечивает восстановление функциональной активности ткани связки или сухожилия за счет поддержания врастания клеток и образования новой ткани. 17 з.п. ф-лы, 12 ил.

УСТРОЙСТВО ДЛЯ КОРРЕКЦИИ МОЛОЧНОЙ ЖЕЛЕЗЫ

ПОЛУЧЕНИЕ ТРАНСПЛАНТАТА ИЗ ДЕРМЫ ЖИВОТНОГО С ПРИМЕНЕНИЕМ РАСТВОРА СУЛЬФИДА НАТРИЯ

... 1. Способ получения трансплантата из дермы животного, предпочтительно из дермы свиньи, включающий в себя следующие стадии:a) подготовка дермы животного;b) обработка дермы животного водным раствором, содержащим сульфид натрия;c) одно- или многократная обработка дермы водным солевым раствором;d) при необходимости одно- или многократная обработка дермы водным раствором пероксида водорода;e) обезвоживание дермы.2. Способ по п.1, отличающийся тем, что на стадии b) применяют водный щелочной раствор, содержащий сульфид натрия.3. Способ по п.1 или 2, отличающийся тем, что на стадии b) применяют водный раствор, содержащий от 0,01 до 10% масс., предпочтительно от 0,1 до 5% масс., более предпочтительно от 0,5 до 3% масс., наиболее предпочтительно от 0,75 до 1,5% масс. и в высшей степени предпочтительно 1% масс. сульфида натрия.4. Способ по п.1, отличающийся тем, что на стадии b) применяют водный раствор, который наряду с сульфидом натрия содержит от 0,001 до 0,5 M, предпочтительно от 0,005 до 0,4 ...

IF EPIDERMALE CULTIVATED CELL LAYER, CULTIVATED HAUTSCHICHT AND PROCEDURE FOR THEIR PRODUCTION LAMINATED

Tissue scaffolds

Tissue scaffolds are described herein. Also described are devices for treating wounds and methods of treating wounds using tissue scaffolds.

Artificial skin

A process for producing an artificial skin, characterized by adding a matrix metalloprotease inhibitor and a heparanase inhibitor to a culture medium for artificial skin formation purposes which contains keratinocytes derived from a human epidermis and fibroblasts derived from a human dermis and culturing the cells contained in the culture medium, thereby forming the artificial skin.

Methods and systems for stiffening of tissue for improved processing

Methods and systems for stiffening of tissue are presented to allow improved processing. Solutions comprising an acid or a base can be contacted with tissue to stiffen one or more components of the tissue. The resulting stiffened tissue can be used in the creation of wound treatment devices.

Breast treatment device

The present disclosure provides devices and methods for treating the breast. The devices (10) can include an acellular tissue matrix having a predefined shape. The shape can include a first edge (16) with an S-shaped configuration and a second arcuate-shaped edge (18). The shape alternatively can include a first concave edge and a second convex edge.

Method for producing artificial skin having hair follicles, sebaceous glands, and pores

... [Problem] The present invention addresses the problem of providing an artificial skin having hair follicles, sebaceous glands, and pores. [Solution] Provided is a method for producing an artificial skin that has hair follicles, sebaceous glands, and pores, the method is characterized by comprising: (A) a step for preparing an artificial skin having a dermal layer and an epidermal layer or an artificial skin only having a dermal layer; and (B) a step for transplanting isolated hair follicles to the artificial skin prepared in step (A), wherein the isolated hair follicles each have a sebaceous gland, and the isolated hair follicles are transplanted to the artificial skin in such a manner that the surface of the dermal layer of the artificial skin and the positions of the pore sections of the hair follicles come into alignment with each other.

Methods for localized modification of tissue products

Methods for treating tissue matrices and tissue matrices produced according to the methods are provided. The methods can include treating select portions of a tissue matrix with a fluid containing at least one agent to produce a tissue matrix with variable mechanical and/or biological properties ...

Transglutaminase treated products

The present application relates to use of transglutaminases to treat various products, including medical devices such as tissue grafts, tissue matrices or other tissue-derived materials, and synthetics. The transglutaminases can be applied to the medical devices to provide advantages such as adhesion resistance or abrasion resistance.

SOFT TISSUE REPAIR GRAFTS AND PROCESSES FOR PREPARING AND USING SAME

Soft tissue repair grafts are provided for supporting, covering, and/or retaining an implant positioned in the body of a subject. The grafts are particularly suitable for use for pre-pectoral breast reconstruction with a breast implant or tissue expander. The grafts include positional 5 notches for more accurate positioning in a subject. The grafts also include at least one cuff element which is folded to form a reinforced folded edge for suturing the graft more securely to adjacent tissues than previously known grafts. The grafts also include a plurality of arcuate slots which form a plurality of circular patterns arranged concentrically about a focal point, thereby enabling the grafts to expand without tearing and to conform more closely to the implant and/or adjacent .0 body tissues such as the breast pocket, than previously known grafts. Acellular dermal matrices are particularly suitable for making the soft tissue repair grafts. 42f 42g 1 - ~42e 42a42/ S 42d 144 30 5,42bl d ...

Materials and methods for protecting against neuromas

The subject invention provides devices and methods for alleviating discomfort associated with neuroma formation. The devices and methods of the invention effectively use the body's natural response of reconstructing implanted biomaterials to minimize the size of, isolate, and protect a neuroma. In preferred embodiments, the subject device is a cylindrical cap, wherein the internal chamber of the cylindrical cap physically partitions the nerve to enable an arrangement of nerve fibers (as opposed to haphazardly arranged nerve fibers often produced in neuromas). Tabs arranged on the outside of the cap can be used to manipulate the cap into place on a nerve. The open end can also be configured with flaps that can be used to widen the open end for easier insertion of the nerve into the cap. In addition, the cap's material remodels into a tissue cushion after implantation, which protects the neuroma from being stimulated and inducing pain.

Decellularization method for preparing extracellular matrix support material

A decellularization method for preparing an extracellular matrix (ECM) support material and an ECM prepared by using same. The method comprises performing decellularization processing on a to-be-processed tissue and organ by using a glucopyranoside solution and a nuclease solution.

Polymer-permeated grafts and methods of making and using the same

This invention is directed to polymer-permeated grafts and methods of making and using the same.

RESORBABLE IMPLANT MATERIALS

A non-crosslinked, decellularized and purified mammalian tissue (e.g., bovine pericardium) having particular use as an implantable resorbable material. The material is treated by alkylating its primary amine groups in a manner sufficient to reduce the antigenicity of the tissue, permitting the treated tissue to be used in vivo and without crosslinking, and in turn, permitting it to be resorbable. The material can be used in surgical repair of soft tissue deficiencies for a certain period of time while the implant itself is gradually remodeled or absorbed by the host. Also provided are a method of preparing such a material as well as a method of using such a material for surgical repair.

DRIED IMPLANT COMPOSITION AND INJECTABLE AQUEOUS IMPLANT FORMULATION

The invention relates to: - A dried implant composition consisting essentially of a mixture of nanocrystalline hydroxyapatite particles derived from natural bone having a size of 50 to 200 µm and fragments of naturally crosslinked fibrous collagen material that pass through a 0.5 mm sieve, whereby the w/w ratio of hydroxyapatite to collagen is from 1.8 to 4.5; - the use of that dried implant composition for preparing an injectable aqueous implant formulation for use in oral tissue regeneration that is extrudable through a tapering system and a gauge 18 (0.838 mm inner diameter) 25.4 mm long cannula; - an injectable aqueous implant formulation for use in oral tissue regeneration, wherein the injectable aqueous implant formulation is obtainable by rehydration and homogeneous mixing of 25-45 w/w % of the above dried implant composition with sterile water or a sterile isotonic saline solution, which can be extruded through a tapering system and an 8 gauge (0.838 mm inner diameter) 25.4 mm long ...

METHODS AND SYSTEMS FOR STIFFENING OF TISSUE FOR IMPROVED PROCESSING

Methods and systems for stiffening of tissue are presented to allow improved processing. Solutions comprising an acid or a base can be contacted with tissue to stiffen one or more components of the tissue. The resulting stiffened tissue can be used in the creation of wound treatment devices.

COMPOSITE MEDICAL GRAFTS AND METHODS OF USE AND MANUFACTURE

Provided in this disclosure are various composite grafts having a trabecular scaffold with voids defined in at least a portion of the scaffold and a biological component positioned in at least some of the voids of the scaffold. The grafts may have a synthetic scaffold or a bone substrate scaffold. The grafts may be osteogenic, chondrogenic, osteochondrogenic, or vulnerary in nature. Also provided are methods of using the composite grafts to treat a tissue defect in a subject. Methods of manufacturing are also provided. Synthetic scaffolds are manufactured by additive manufacturing. Agitation is used to combine the biological component with the scaffold of the graft.

ACELLULAR TISSUE MATRIX PARTICLES AND FLOWABLE PRODUCTS COMPRISING THEM

The present disclosure provides tissue fillers. The tissue fillers can include a plurality of tissue particles formed from acellular tissue matrix fragments. The tissue fillers can be used to fill tissue sites, such as voids formed after tissue resection.

TISSUE SCAFFOLD COMPRISING AN ACELLULAR TISSUE MATRIX AND SODIUM ACETATE

Tissue scaffolds, and methods of processing thereof, are described herein. Also described are devices for treating wounds and methods of treating wounds using tissue scaffolds. The tissue scaffolds are prepared with sodium acetate to control the porosity, strut density, and permeability of the scaffolds.

Production method for cryopreserved acellular dermal matrix, and cryopreserved acellular dermal matrix produced thereby

Graft materials for surgical breast procedures

피부-확대용 수술 봉합물

... 본 발명은 피부와 같은 인간 조직내로 피부-보강 물질을 도입시키기 위한 수술용 봉합사 및 실에 관한 것이다.

Biologic treatment system and method

A delivery system is provided that is adapted to treat various urological pelvic disorders, such as prolapse, incontinence, and the like. The delivery system can include at least one biologic loaded or otherwise provided with a bioactive agent. The biologic can comprise any drugs, hormones or steroids, stem cells, growth factors, proteins, and/or other bioactive agents to promote cell or tissue growth for the treatment and strengthening of organ walls or tissue. The biologic is generally adapted to controllably release the agent to the surrounding tissue or organ to provide a local and targeted delivery.

Double cross-linkage process to enhance post-implantation bioprosthetic tissue durability

Bioprosthetic tissues and methods for making same, comprising fixing bioprosthetic implant tissue by treatment with 0.1 to 10 wt. % glutaraldehyde at elevated temperature, capping said fixed tissue by treatment with a diamine crosslinking agent, and treating said capped tissue with about 0.6 wt. % glutaraldehyde.

Artificial skin

The present invention relates to a method for producing artificial skin, comprising: adding a matrix metalloproteinase inhibitor and a heparanase inhibitor to an artificial skin formation culture medium comprising human epidermal keratinocytes and human dermal fibroblasts, culturing the cells in the artificial skin formation culture medium, and forming artificial skin.

Engineered Tissue Implants And Methods Of Use Thereof

A engineered tissue implant comprising a perfusion chamber formed with a biocompatible flexible tubular member having a wall defining an internal fluid flow passage and a porous scaffold within the fluid flow passage of the tubular member, the porous scaffold arranged such that, in a presence of a perfusion fluid, the perfusion fluid will flow through the porous scaffold and be inhibited from flow between the porous scaffold and the wall of the tubular member. The engineered tissue implant may be understood as a transplantable cell construct or as an implantable bioreactor for cell growth both in vitro and/or in vivo. A method to provide tissue for reconstruction may comprise forming the engineered tissue implant containing a scaffold, introducing and seeding cells to the scaffold, introducing a perfusion fluid to the scaffold which flows through the fluid flow passage and scaffold, proliferating the cells within the scaffold and forming blood vessels within the scaffold. This may be followed by transplanting the engineered tissue implant in vivo where nutrition and oxygen are provided to support the preloaded cells.

Device and method for replacing mitral valve

A prosthetic mitral valve assembly is disclosed. The assembly comprises a radially-expandable stent including a lower portion sized for deployment between leaflets of a native mitral valve and an upper portion having a flared end. The upper portion is sized for deployment within the annulus of the mitral valve and the flared end is configured to extend above the annulus. The stent is formed with a substantially D-shape cross-section for conforming to the native mitral valve. The D-shape cross-section includes a substantially straight portion for extending along an anterior side of the native mitral valve and a substantially curved portion for extending along a posterior side of the native mitral valve. The assembly further includes a valve portion formed of pericardial tissue and mounted within an interior portion of the stent for occluding blood flow in one direction.

Compositions for Regenerating Defective or Absent Myocardium

Compositions of the invention for regenerating defective or absent myocardium comprise an emulsified or injectable extracellular matrix composition. The composition may also include an extracellular matrix scaffold component of any formulation, and further include added cells, proteins, or other components to optimize the regenerative process and restore cardiac function.

Unitary Endoscopic Vessel Harvesting Devices

Unitary surgical devices are disclosed. Such devices may include an elongated body extending between a proximal end and a distal end, and having one or more lumens extending through the elongated body and a tip disposed at the distal end of the elongated body. The harvesting device may further include a first gripping element disposed about the dissection tip and a second gripping element disposed about the dissection tip distally of the first gripping member. The second gripping member may be moveable with respect to the first gripping member for capturing a blood vessel between the first gripping member and the second gripping member. The blood vessel captured between first gripping member and the second gripping member may then be sealed and, subsequently, severed by a cauterizing element disposed between the first gripping member and the second gripping member. 1. An surgical device comprising:an elongated body extending between a proximal end and a distal end, and having one or more lumens extending through the elongated body;a tip disposed at the distal end of the elongated body;a first gripping element disposed about the dissection tip;a second gripping element disposed about the dissection tip distally of the first gripping member, the second gripping member being moveable with respect to the first gripping member between an open position away from the first gripping member to a closed position toward the first gripping member for gripping a blood vessel between the first gripping member and the second gripping member; anda cauterizing element disposed between the first gripping member and the second gripping member such that the blood vessel, when gripped between the first gripping member and the second gripping member, is pressed against the cauterizing element for sealing the blood vessel.2. The device of wherein the cauterizing element is further used to sever the blood vessel.3. The device of further comprising controls disposed near the proximal end of ...

Prosthetic heart valve including stent structure and tissue leaflets, and related methods

A method of making a prosthetic heart valve may include providing an annular stent having a plurality of annularly spaced commissure portions having tips, covering each of the tips with a first fabric cover, covering the first fabric covers and the remainder of the stent with a second fabric cover, covering the second fabric cover with a first tissue membrane, and covering the outside of the first tissue membrane with a second tissue membrane, the second tissue membrane forming leaflet portions that extend inwardly between the commissure portions.

Enzyme-activated collagen and tissue matrices

Devices and methods for treating defects in connective tissue are provided along with methods for making such devices. The devices can include enzyme-activated acellular tissue matrices that facilitate regrowth of the damaged tissue.

Flowable matrix compositions and methods

Flowable matrix compositions and methods of their use and manufacture are provided. Exemplary compositions may include a flowable, syringeable, putty-like form of acellular human dermal matrix. In some cases, compositions may include a moldable acellular collagen extracellular matrix. In use, the matrix compositions can be used to fill or treat skin voids, channel wounds, and other soft tissue deficiencies.

Methods of conditioning sheet bioprosthetic tissue

Methods for the conditioning of bioprosthetic material employ bovine pericardial membrane. A laser directed at the fibrous surface of the membrane and moved relative thereto reduces the thickness of the membrane to a specific uniform thickness and smoothes the surface. The wavelength, power and pulse rate of the laser are selected which will smooth the fibrous surface as well as ablate the surface to the appropriate thickness. Alternatively, a dermatome is used to remove a layer of material from the fibrous surface of the membrane. Thinning may also employ compression. Stepwise compression with cross-linking to stabilize the membrane is used to avoid damaging the membrane through inelastic compression. Rather, the membrane is bound in the elastic compressed state through addition cross-linking. The foregoing several thinning techniques may be employed together to achieve strong thin membranes.

Nanofiber scaffolds and methods for repairing skin damage

A composition is provided that includes a plurality of layered nanofiber scaffolds. A first nanofiber scaffold can include microwells configured to be seeded with one or more relevant cells, a skin tissue, or combinations thereof. Furthermore, the first nanofiber scaffold can comprise uniaxially aligned nanofibers between the microwells and random nanofibers on the microwells. The composite can also include a second nanofiber scaffold that comprises radially-aligned nanofibers. Further provided are methods for making such a composition as well as methods for treating damaged skin that include applying an effective amount of the composition to a site of damaged skin on a subject.

TISSUE GRAFTING METHOD

The tissue grafting method relates to a tissue graft material, a method of preparing the material, and a method of using the material. The tissue graft material is made from the tunica serosa of the small intestine of a warm-blooded vertebrate, which has been delaminated from the tunica muscularis, tunica submucosa, and the tunica mucosa of the intestinal tissue. The tissue graft material may be perforated by discrete punctures. The tissue graft material is dehydrated by air drying or vacuum drying, sterilized with ethylene oxide, and stored in a hermetically sealed enclosure at room temperature until needed, having an indefinite storage life. When needed, the tissue graft material is rehydrated, cut to match the size of the wound, and applied to the wound. The graft may be overlaid with nylon mesh, or bandaged with an elastic tubular dressing. 1. A tissue grafting method for treating wounds on a surface area , comprising the steps of:treating a surface area requiring a skin graft with an antiseptic to produce a cleansed graft zone;cutting a tissue graft consisting of the tunica serosa from the small intestine of porcine tissue into a planar shape having a size substantially corresponding to the cleansed graft zone; andlayering the porcine tissue graft onto the cleansed graft zone to produce a dressed graft zone.2. The tissue grafting method according to claim 1 , further comprising the step of rehydrating the tissue graft prior to the step of cutting the tissue graft if the tissue graft has been stored in a dehydrated state.3. The tissue grafting method according to claim 1 , further comprising the step of covering the dressed graft zone with nylon mesh.4. The tissue grafting method according to claim 1 , further comprising the step of covering the dressed graft zone with an elastic claim 1 , tubular bandage.5. The tissue grafting method according to claim 1 , further comprising the step of exposing the dressed graft zone to light for desiccation.6. The tissue ...

Process for Devitalizing Soft-Tissue Engineered Medical Implants and Devitalized Soft-Tissue Medical Implants Produced

The invention provides methodologies and apparatus for producing acellular soft-tissue implants, both in small quantities and in commercializable quantities. Such soft-tissue implants include vascular graft substitutes. An acellular graft is produced by subjecting the tissue sample to an induced pressure mediated flow of an extracting solution, followed by inducing a pressure mediated flow of a treating solution, then washing the treated tissue to produce the acellular graft. The acellular grafts produced are uniform and nonimmunogenic. 1. A process for preparing an acellular soft tissue graft for implantation into a mammalian system , comprising:extracting a soft tissue sample with an extracting solution comprising one or more nonionic detergents and one or more endonucleases, to produce extracted tissue;treating said extracted tissue with a treating solution comprising one or more anionic detergents, to produce a treated tissue;washing said treated tissue with a decontaminating solution comprising one or more decontaminating agents to produce said acellular soft tissue graft; andstoring said acellular soft tissue graft in a storage solution comprising one or more decontaminating agents.2. A process for preparing commercializable quantities of acellular soft tissue grafts for implantation into mammalian systems , comprising:obtaining tissue samples from an acceptable donor; extracting said tissue samples with an extracting solution comprising one or more nonionic detergents and one or more endonucleases, to produce extracted tissue;treating said extracted tissue with a treating solution comprising one or more anionic detergents, to produce a treated tissue;washing said treated tissue with a decontaminating solution comprising one or more decontaminating agents; to produce said acellular soft tissue graft; andstoring said acellular soft tissue graft in a storage solution comprising one or more decontaminating agents.3. A process for preparing an acellular soft ...

TISSUE AUGMENTATION SCAFFOLDS FOR USE IN SOFT TISSUE FIXATION REPAIR

Devices, systems, and methods to improve both the reliability of soft tissue repair procedures and the speed at which the procedures are completed are provided. The devices and systems include one or more tissue augmentation constructs, which include constructs that are configured to increase a footprint across which suture applied force to tissue when the suture is tied down onto the tissue. The tissue augmentation constructs can be quickly and easily associated with the repair suture, and can be useful in many different tissue repair procedures that are disclosed in the application. Tissue augmentation constructs can include various blocks and scaffolds, among other formations. The present disclosure includes, among other disclosures, methods for using tissue augmentation scaffolds, including folding scaffolds, and descriptions and methods associated with extra-wide tissue augmentation blocks. 1. A method of soft tissue repair , comprising:passing a first suture through soft tissue from a medial suture anchor disposed in bone at a surgical repair site below the soft tissue such that a first suture limb and a second suture limb of the first suture extends from the soft tissue;passing a second suture from the medial suture anchor through the soft tissue such that a first suture limb and a second suture limb of the second suture extends from the soft tissue;installing a medial row stitch on the second suture to secure the soft tissue to the bone;threading the first suture limb of the first suture through a channel in a tissue augmentation scaffold;delivering the tissue augmentation scaffold to the surgical repair site;coupling the first suture limb of the first suture to a first lateral suture anchor disposed in bone after the tissue augmentation scaffold has been delivered to the surgical repair site; andpassing the second suture limb of the first suture across a top face of the tissue augmentation scaffold, after the tissue augmentation scaffold has already been ...

Crosslinked Soft Tissue Graft and Methods of Use Thereof

The invention relates to crosslinked soft tissue grafts and methods of use thereof. The invention also relates to methods of preparing the same. 1. A crosslinked soft tissue graft for implantation and tissue defect repair , wherein the soft tissue graft is resistant to enzymatic degradation and stretching under tension , wherein the cellular infiltration after implantation is maintained.2. A method of preparing a crosslinked soft tissue graft , comprising:(i) selecting a soft tissue graft,(ii) optionally decellularizing said soft tissue graft,(iii) incubating the soft tissue graft with the crosslinking agent,(iv) removing the crosslinking agent after the incubation period,(v) optionally rinsing the crosslinked soft tissue in a buffer without the crosslinking agent,(vi) optionally treating the crosslinked soft tissue graft with a plasticizer,(vii) optionally packaging the crosslinked soft tissue graft, and(viii) optionally sterilizing the crosslinked soft tissue graft.3. The method according to claim 2 , wherein the soft tissue graft is incubated for 1 day.4. The method according to claim 2 , wherein the crosslinked soft tissue is rinsed for 1 day.5. The method according to claim 2 , comprising decellularizing said soft tissue graft.6. The method according to claim 2 , comprising rinsing the crosslinked soft tissue in a buffer without the crosslinking agent.7. The method according to claim 2 , comprising treating the crosslinked soft tissue graft with a plasticizer. The method according to claim 2 , comprising packaging the crosslinked soft tissue graft.9. The method according to claim 2 , comprising sterilizing the crosslinked soft tissue graft.10. A crosslinked soft tissue graft prepared by the method according to .118. The soft tissue graft according to any and claims 1 , wherein said soft tissue graft is crosslinked in a degree from about 10% to about 60%.1289. The soft tissue graft according to any and - claims 1 , wherein the crosslinking is through forming ...

XENOTRANSPLANTATION PRODUCTS AND METHODS

A biological product for clinical xenotransplantation into a human and a method of preparing biological product for clinical xenotransplantation into a human involving producing a non-wild type, biologically engineered swine having a biologically engineered genome such that the swine does not express one or more extracellular surface glycan epitopes, is free of certain pathogens, is reared according to a bioburden-reducing procedure in a closed designated pathogen free herd, wherein the biological product is harvested following the swine being euthanized and the product is aseptically removed from the swine, the biological product is processed involving sterilization and storing the product in a sterile container, and the product does not contain one or more extracellular surface glycans, is free of certain designated pathogens, is biologically active and comprises live cells and tissues capable of vascularizing after xenotransplantation. 1. A biological product for xenotransplantation into a human recipient , said biological product comprising live cells and tissue that vascularize after xenotransplantation , A) has a biologically engineered genome such that it does not express one or more extracellular surface glycan epitopes,', [{'i': Ascaris', 'cryptosporidium', 'Echinococcus, Strongyloids sterocolis', 'Toxoplasma gondii, '(i) species, species, , and in fecal matter;'}, {'i': Leptospira', 'Mycoplasma', 'Toxoplasma Gondii, '(ii) species, hyopneumoniae, porcine reproductive and respiratory syndrome virus (PRRSV), pseudorabies, transmissible gastroenteritis virus (TGE)/Porcine Respiratory Coronavirus, and by determining antibody titers;'}, '(iii) Porcine Influenza;', {'i': Bordetella bronchisceptica', 'Staphylococcus aureus', 'Microphyton', 'Trichophyton, '(iv) the following bacterial pathogens as determined by bacterial culture: , Coagulase-positive staphylococci, Coagulase-negative staphylococci, Livestock-associated methicillin resistant (LA MRSA), and spp.;'}, ...

SYSTEMS FOR DRYING SHEETS OF DONOR-PROVIDED HUMAN TISSUE

Embodiments of this technology may include an apparatus for drying tissue. The apparatus may include human donor tissue placed in contact with and between at least two layers of backing material. This tissue and backing layer may then be restrained by two plates. This tissue may be amniotic tissue. The backing layer may include woven or nonwoven material. This backing layer may be wetted with a saline solution. At least one of the plates of the tissue drying apparatus may be perforated. The tissue assembly along with the plates may then be placed inside a chamber configured to receive the plates and tissue assembly. The chamber may be configured so that gas can be forced into the chamber with the gas flow going around the plates and the tissue assembly. 1. An apparatus for drying human donor tissue for administration to a recipient patient , the apparatus comprising:the human donor tissue;placed in contact with a backing layer, a first plate, and a second plate, wherein the first plate and the second plate restrain the human donor tissue and the backing layer.2. The apparatus of claim 1 , wherein the human donor tissue is placed in contact with a second backing layer.3. The apparatus of claim 1 , further comprising a chamber configured to receive the first plate claim 1 , the second plate claim 1 , the human donor tissue claim 1 , and the backing layer.4. The apparatus of claim 3 , wherein the chamber is configured to allow forced gas to flow around the first plate and the second plate.5. The apparatus of claim 3 , wherein the chamber is configured for heating.6. A system for drying human donor tissue for administration to a recipient patient claim 3 , the system comprising:a first plate;a second plate;a chamber;a gas inlet; the chamber is configured to receive the first plate and the second plate,', 'the gas inlet is in fluid communication with the chamber,', 'the chamber is configured such that when the first plate and the second plate are disposed in the chamber, ...

BONE AUGMENTATION UTILIZING MUSCLE-DERIVED PROGENITOR COMPOSITIONS IN BIOCOMPATIBLE MATRIX, AND TREATMENTS THEREOF

The present invention provides muscle-derived progenitor cells that show long-term survival following transplantation into body tissues and which can augment non-soft tissue following introduction (e.g. via injection, transplantation, or implantation) into a site of non-soft tissue (e.g. bone) when combined with a biocompatible matrix, preferably SIS. The invention further provides methods of using compositions comprising muscle-derived progenitor cells with a biocompatible matrix for the augmentation and bulking of mammalian, including human, bone tissues in the treatment of various functional conditions, including osteoporosis, Paget's Disease, osteogenesis imperfecta, bone fracture, osteomalacia, decrease in bone trabecular strength, decrease in bone cortical strength and decrease in bone density with old age. 134.-. (canceled)35. A method of treating a bone disease , defect or pathology in a human subject in need thereof , wherein the method comprises administering to the human subject small intestine submucosa (SIS) seeded with a cell population enriched for muscle derived progenitor cells (MDCs) , wherein the cell population enriched for MDCs is isolated from skeletal muscle by a method comprising:a. suspending skeletal muscle cells obtained from the human in a first cell culture container for between 30 and 120 minutes to produce a population of adherent cells and a population of non-adherent cells;b. decanting media and the population of non-adherent cells from the first cell culture container to a second cell culture container;c. allowing the population of decanted, non-adherent cells in the media to attach to the walls of the second cell culture container; andd. isolating the population of cells from the walls of the second cell culture container, wherein the isolated population of cells is the cell population enriched for MDCs.36. The method of claim 35 , wherein the isolation method further comprises culturing the cell population enriched for MDCs to ...

REVASCULARIZATION GRAFT MATERIAL

Provided is a graft material capable of securing a sufficient space for regenerated tissue in the implantation site, and thereby promoting the regeneration of a blood vessel. Specifically, the present invention provides a revascularization graft material including an outer tube and an inner tube each being formed by knitting twisted yarns of biodegradable single yarns into a hollow tubular structure, wherein there is provided, in the lumen of the outer tube, at least one inner tube having an outer diameter smaller than the lumen diameter of the outer tube. The inner tube functions as a core material for the outer tube, and accordingly the revascularization graft material is excellent in kinking resistance, and the occlusion of the lumen hardly occurs. 1. A revascularization graft material comprising an outer tube and an inner tube each being formed by knitting twisted yarns of biodegradable single yarns into a hollow tubular structure , wherein there is provided , in the lumen of the outer tube , at least one inner tube having an outer diameter smaller than the lumen diameter of the outer tube.2. The graft material according to claim 1 , wherein the graft material is provided claim 1 , in the lumen of the outer tube claim 1 , with a space formed of the lumen internal surface of the outer tube and the external surface of the inner tube.3. The graft material according to claim 1 , wherein to the outer tube and/or the inner tube claim 1 , one or more factors selected from the group consisting of vascular endothelial growth factor (VEGF) claim 1 , platelet-derived growth factor (PDGF) claim 1 , fibroblast growth factor (FGF) and/or hepatocyte growth factor (HGF) are bound.4. The graft material according to claim 3 , wherein one or more factors selected from the group are bound to the outer tube claim 3 , and one or more other factors selected from the group are bound to the inner tube.5. The graft material according to claim 4 , wherein vascular cells and/or cells to ...

Decellularized soft-tissue grafts

The invention provides methodologies and apparatus for producing acellular soft-tissue implants, both in small quantities and in commercializable quantities. Such soft-tissue implants include vascular graft substitutes. An acellular graft is produced by subjecting the tissue sample to an induced pressure mediated flow of an extracting solution, followed by inducing a pressure mediated flow of a treating solution, then washing the treated tissue to produce the acellular graft. The acellular grafts produced are uniform and nonimmunogenic. The inventive method allows for the production of multiple decellularized soft tissue implants, where processing time is significantly less than prior art processes and the number of implants produced per day is increased over prior art processes. In clinical use, the decellularized grafts produced exhibit significantly improved in long-term durability and function.

Methods for Regenerating Defective or Absent Myocardium

A method for treating damaged or diseased mammalian tissue that includes the steps of (i) providing a sheet structure formed from acellular dermal mammalian tissue that includes extracellular matrix (ECM) and a supplemental bioactive component, such as a nucleic acid, and/or a cell, and (ii) delivering the sheet structure to the damaged or diseased mammalian tissue, wherein the sheet structure induces angiogenesis and, thereby, regeneration of new mammalian tissue. 1. A method for regenerating damaged or diseased mammalian tissue , comprising the steps of:providing a sheet structure comprising acellular dermal mammalian tissue, said acellular dermal mammalian tissue comprising extracellular matrix (ECM),said ECM comprising collagen type I, collagen type III, proteoglycans, transforming growth factor beta (TGF-β) and fibroblast growth factor-2 (FGF-2),said acellular dermal mammalian tissue further comprising a supplemental bioactive component comprising an exogenously added cell selected from the group consisting of an embryonic stem cell, a mesenchymal cell, and a hematopoietic stem cell,said exogenously added cell being linked to said ECM, wherein said exogenously added cell interacts with at least one molecule in said ECM, whereby, when said acellular dermal mammalian tissue is disposed proximate to damaged mammalian tissue, said acellular dermal mammalian tissue induces angiogenesis; anddelivering said sheet structure to said damaged or diseased mammalian tissue, wherein said sheet structure induces regeneration of new mammalian tissue.2. The method of claim 1 , wherein said damaged or diseased mammal tissue comprises damaged or diseased cardiovascular tissue.3. The method of claim 2 , wherein said exogenously added cell comprises a cell selected from the group consisting of a neonatal cardiomyocyte claim 2 , a fetal cardiomyocyte and a myofibroblast.4. A method for regenerating damaged or diseased mammalian tissue claim 2 , comprising the steps of:providing a ...

Compositions and Structures for Regenerating Defective or Absent Myocardium

Sheet structures for regenerating damaged or diseased mammalian tissue that are formed from acellular dermal mammalian tissue. The acellular dermal mammalian tissue includes extracellular matrix (ECM) and a supplemental bioactive component. The supplemental bioactive component can comprise a nucleic acid, such as RNA, and/or a cell, such as an embryonic stem cell. The sheet structures induce angiogenesis and, thereby, regeneration of new mammalian tissue. 1. A sheet structure for regenerating damaged or diseased mammalian tissue , comprising:acellular dermal mammalian tissue, said acellular dermal mammalian tissue comprising extracellular matrix (ECM),said ECM comprising collagen type I, collagen type III, proteoglycans, transforming growth factor beta (TGF-β) and fibroblast growth factor-2 (FGF-2),said acellular dermal mammalian tissue further comprising a supplemental bioactive component comprising an exogenously added cell selected from the group consisting of an embryonic stem cell, a mesenchymal cell and a hematopoietic stem cell,said exogenously added cell being linked to said ECM, wherein said exogenously added cell interacts with at least one molecule in said ECM, whereby, when said acellular dermal mammalian tissue is disposed proximate to damaged mammalian tissue, said acellular dermal mammalian tissue induces angiogenesis and, thereby, regeneration of new mammalian tissue.2. The sheet structure of claim 1 , wherein said damaged mammalian tissue comprises damaged cardiovascular tissue.3. The sheet structure of claim 2 , wherein said exogenously added cell is selected from the group consisting of a neonatal cardiomyocyte claim 2 , a fetal cardiomyocyte and a myofibroblast.4. The sheet structure of claim 1 , wherein said acellular dermal mammalian tissue comprises a physical formulation selected from the group consisting of a solid sheet claim 1 , a multilaminate sheet claim 1 , a weave claim 1 , a strip claim 1 , a patch and a vacuum pressed material.5. A ...

METHODS OF BIOENGINEERING INTERNAL ANAL SPHINCTER CONSTRUCTS

The present disclosure provides methods of bioengineering sphincters having autologous smooth muscle cells isolated from human internal anal sphincter and autologous enteric neurospheres (neural progenitor cells) isolated from human small intestine (jejunum). The isolated neural progenitor cells and smooth muscle cells are co -cultured using dual layered hydrogels and allowed to form circular, intrinsically innervated internal anal sphincter constructs. Such innervated internal anal sphincter constructs, bioengineered internal anal sphincter constructs are useful as additive implants in the treatment of fecal incontinence. 1. A method of generating an innervated internal anal sphincter construct , comprising:obtaining an anorectum tissue cell biopsy from a subject;obtaining an intestinal tissue cell biopsy from the subject;isolating smooth muscle cells from the anorectum tissue cell biopsy;isolating neural progenitor cells from the intestinal tissue cell biopsy;seeding a multi-layer gel matrix on a mold, comprising at least a one gel layer of isolated smooth muscle cells and at least another gel layer of isolated neural progenitor cells in contact with one another, wherein the matrix is seeded in a substantially circular shape; andcontacting the multi-layer gel matrix with a differentiation media to induce differentiation of the neural progenitor cells, thereby forming the innervated construct having directionally oriented smooth muscle cells.2. The method of claim 1 , wherein the step of obtaining the anorectum tissue cell biopsy further comprises a step of obtaining the biopsy from the subject's internal anal sphincter tissue.3. The method of claim 1 , wherein the step of obtaining the intestinal tissue cell biopsy further comprises a step of obtaining the biopsy from the subject's jejunal small intestine tissue.4. The method of claim 1 , wherein at least one of the steps of obtaining the anorectum tissue cell biopsy and obtaining the intestinal tissue cell biopsy ...

Flowable Matrix Compositions and Methods

Flowable matrix compositions and methods of their use and manufacture are provided. Exemplary compositions may include a flowable, syringeable, putty-like form of acellular human dermal matrix. In some cases, compositions may include a moldable acellular collagen extracellular matrix. In use, the matrix compositions can be used to fill or treat skin voids, channel wounds, and other soft tissue deficiencies. 1. A method for producing a soft tissue matrix composition for use in a patient treatment , the method comprising:providing a human soft tissue material; andprocessing the human soft tissue material by cryofracturing the human soft tissue material,wherein the processing provides the soft tissue matrix composition.2. The method according to claim 1 , wherein the human soft tissue material is acellular.3. The method according to claim 1 , wherein the human soft tissue material is at least partially decellularized.4. The method according to claim 1 , wherein the human soft tissue material is not partially or completely decellularized.5. The method according to claim 1 , wherein the processing further comprises triturating the cryofractured human soft tissue material.6. The method according to claim 5 , wherein the triturating comprises milling the cryofractured human soft tissue material.7. The method according to claim 6 , wherein the processing further comprises adding a wetting agent to the triturated soft tissue material.8. The method according to claim 7 , wherein the wetting agent comprises a saline solution.9. The method according to claim 1 , wherein the soft tissue matrix composition has a putty consistency.10. The method according to claim 1 , wherein the human soft tissue material is in a naturally hydrated state prior to processing.11. The method according to claim 1 , wherein the human soft tissue material is in a partially hydrated state prior to processing.12. The method according to claim 1 , wherein the human soft tissue material is in a dehydrated ...

Soft Tissue Pouch and Methods of Use Thereof

The invention relates to a soft tissue pouch and methods of use thereof. 1. A medical product comprising a medical device and a soft tissue pouch encapsulating the medical device.2. The medical product according to claim 1 , wherein the soft tissue is selected from skin claim 1 , dermis claim 1 , pericardium claim 1 , fascia claim 1 , arteries or veins claim 1 , dura mata claim 1 , ammonic membrane claim 1 , bladder claim 1 , small or large intestine.32. The medical product according to any of - claims 1 , wherein the soft tissue is an autograft claims 1 , an allograft claims 1 , or a xenograft.43. The medical product according to any of - claims 1 , wherein the soft tissue is dermis.54. The medical product according to any of - claims 1 , wherein the basement membrane side of the soft tissue is placed outward.65. The medical product according to any of - claims 1 , wherein the medical device is a pacemaker claims 1 , an ICD claims 1 , an insulin pump claims 1 , or an indwelling catheter.7. A method for preparing a soft tissue pouch for implanting a medical device into a patient claims 1 , comprising:(i) obtaining a mammalian soft tissue;(ii) optionally decellularizing and/or devitalizing the soft tissue;(iii) optionally treating the soft tissue with a plasticizer;(iv) suturing, stapling or gluing the soft tissue into a pouch shape configured to encapsulate a medical device;(v) packaging the soft tissue pouch in a packaging material; and(vi) optionally sterilizing the product.8. A method for implanting a medical device into a patient claims 1 , comprising(i) encapsulating the medical device into a soft tissue pouch;(ii) closing the opening of soft tissue pouch; and(iii) implanting the medical device with the soft tissue pouch.9. The method according to or claims 1 , wherein the soft tissue is selected from skin claims 1 , dermis claims 1 , pericardium claims 1 , fascia claims 1 , arteries or veins claims 1 , dura mata claims 1 , ammonic membrane claims 1 , bladder ...

Flowable Matrix Compositions and Methods

Flowable matrix compositions and methods of their use and manufacture are provided. Exemplary compositions may include a flowable, syringeable, putty-like form of acellular human dermal matrix. In some cases, compositions may include a moldable acellular collagen extracellular matrix. In use, the matrix compositions can be used to fill or treat skin voids, channel wounds, and other soft tissue deficiencies. 153-. (canceled)54. A soft tissue matrix composition for use in a patient treatment , the composition consisting of:a cryofractured human soft tissue material having a mechanically disrupted extracellular matrix collagen or macrostructure and a partially disrupted collagen microfibrillar architecture, wherein the cryofractured tissue material is in a hydrated state, the hydration comprising the natural interstitial water of the cryofractured soft tissue material that is present prior to cryofractionation; anda wetting agent, wherein the wetting agent is at least one wetting agent selected from the group consisting of water, saline solution, phosphate buffered saline (PBS), sodium dodecyl sulfate, sodium stearate, benzalkonium chloride, 3-[(3-cholamidopropyl)dimetylammonio]-1-propanesulfonate (CHAPS), lecithin, Triton X-100, and nonoxynol-9.55. The soft tissue matrix composition according to claim 54 , wherein the soft tissue matrix composition is present in an applicator assembly.56. The soft tissue matrix composition according to claim 54 , wherein the human soft tissue material is acellular.57. The soft tissue matrix composition according to claim 54 , wherein the human soft tissue material is at least partially decellularized.58. The soft tissue matrix composition according to claim 54 , wherein the human soft tissue material is not partially or completely decellularized.59. The soft tissue matrix composition according to claim 54 , wherein the soft tissue matrix composition does not adhere to a surgical glove material.60. The soft tissue matrix composition ...

TISSUE MATRICES INCORPORATING MULTIPLE TISSUE TYPES

The present disclosure provides tissue products produced from extracellular tissue matrices. The tissue products can include acellular extracellular matrices including combinations of different tissue types. The combination can harness various properties of the different tissues to provide improved composite structures with desired mechanical and/or biologic properties. 1. A tissue product , comprising:a first component comprising an intact acellular tissue matrix; anda second component comprising a porous acellular tissue matrix sponge covering at least a portion of the intact acellular tissue matrix, wherein the porous acellular tissue matrix sponge comprises a tissue matrix that has been mechanically homogenized, resuspended, and stabilized, and wherein the intact acellular tissue matrix and porous acellular tissue matrix sponge are attached such that the intact acellular tissue matrix provides mechanical support to the porous acellular tissue matrix sponge.2. The tissue product of claim 1 , wherein the intact acellular tissue matrix comprises a dermal tissue matrix.3. The tissue product of claim 1 , wherein the porous acellular tissue matrix sponge comprises an adipose tissue matrix.4. The tissue product of claims 1 , wherein the intact acellular tissue matrix is in the form of a sheet.5. The tissue product of claim 4 , wherein the porous acellular tissue matrix sponge covers at least one side of the sheet.6. The tissue product of claim 4 , wherein at least a portion of a surface of the intact acellular tissue matrix is textured claim 4 , roughened claim 4 , or indented.7. The tissue product of claim 1 , further comprising at least one additional acellular tissue matrix claim 1 , comprising a skeletal muscle matrix.8. The tissue product of claim 1 , wherein the first component comprising an intact acellular tissue matrix comprises a group of openings.9. The tissue product of claim 8 , wherein the intact acellular tissue product is in the form of a sheet claim 8 ...

Prosthetic Tissue Valves

A prosthetic valve comprising a conical shaped ribbon structure comprising an extracellular matrix (ECM) composition. The ribbon structure comprises a plurality of elongated ribbon members that are positioned proximate each other in a joined relationship, wherein the ribbon members are positioned adjacent each other and form a plurality of fluid flow modulating regions that open when fluid flow through the valve exhibits a negative flow pressure and open when fluid flow through the valve exhibits a positive flow pressure. 1. A prosthetic valve for modulating fluid flow through a cardiovascular structure during cardiac cycles of a heart , said prosthetic valve comprising:a base valve structure comprising an extracellular matrix (ECM) composition, said ECM composition comprising acellular ECM from a mammalian tissue source,said base valve structure further comprising proximal and distal ends, and a ribbon structure comprising a plurality of elongated ribbon members that extend from said valve structure proximal end to said valve structure distal end,each of said plurality of ribbon members comprising proximal and distal ends, said proximal ends of said plurality of ribbon members being positioned circumferentially at said base valve structure proximal end, wherein a valve annulus engagement end of said valve structure is formed,each of said plurality of ribbon members comprising a first edge region that extends from said proximal end to said distal end of said plurality of ribbon members and a second edge region that extends from said proximal end to said distal end of said plurality of ribbon members,said ribbon structure further comprising at least one coupling member that connects said first edge region of a first elongated ribbon member of said plurality of elongated ribbon members to said second edge region of an adjacent second elongated ribbon member of said plurality of elongated ribbon members,said distal ends of said plurality of ribbon members being ...

Extracellular Matrix Tissue Prostheses

Tissue prostheses having a base structure and a physiological sensor system. The tissue prostheses are adapted and configured to induce remodeling of damaged tissue and regeneration of new tissue and concurrently detect and monitor physiological characteristics when implanted in the subject. 1. A tissue prosthesis , comprising:a base structure and a physiological sensor system, said physiological sensor system being joined to said base structure,said base structure comprising an extracellular matrix (ECM) composition comprising acellular ECM from a mammalian tissue source, said base structure, when disposed proximate damaged biological tissue, being adapted to induce modulated healing of said damaged tissue, said modulated healing comprising reducing an inflammatory phase of said damaged tissue and inducing host tissue proliferation, bioremodeling and, thereby, neovascularization of said damaged tissue, and regeneration of new tissue and tissue structures,said base structure and physiological sensor system being jointly adapted to concurrently induce said modulated healing and detect at least one physiological parameter of said subject, when disposed proximate said damaged biological tissue of said subject.2. The tissue prosthesis of claim 1 , wherein said mammalian tissue source comprises mammalian tissue selected from the group consisting of small intestine submucosa (SIS) claim 1 , urinary bladder submucosa (UBS) claim 1 , stomach submucosa (SS) claim 1 , urinary basement membrane (UBM) claim 1 , liver basement membrane (LBM) claim 1 , amniotic membrane claim 1 , mesothelial tissue claim 1 , placental tissue and cardiac tissue.3. The tissue prosthesis of claim 1 , wherein said ECM composition further comprises an additional biologically active agent.4. The tissue prosthesis of claim 3 , wherein said biologically active agent comprises a growth factor selected from the group consisting of a basic fibroblast growth factor (bFGF) claim 3 , transforming growth factor ...

GRAFT MATERIALS FOR SURGICAL BREAST PROCEDURES

Graft materials and devices for surgical breast procedures, as well as methods of making graft devices, are described. 1. A medical implant , comprising:a sample of biocompatible material comprising an acellular tissue matrix, the sample of biocompatible material comprising a first edge consisting essentially of a first convex portion and a second edge consisting essentially of a second convex portion;wherein, when the sample of biocompatible material is in a planar configuration, the first convex portion of the first edge defines a first radius of curvature that extends away from the second edge and the second convex portion of the second edge defines a second radius of curvature that extends away from the first edge, the first radius of curvature being different from the second radius of curvature; andwherein the first and second edges of the sample of biocompatible material are joined to each other at pointed apexes.2. The medical implant of claim 1 , wherein the sample of biocompatible material is sheet-like in form.3. The medical implant of claim 1 , wherein the sample of biocompatible material comprises a single layer sheet.4. The medical implant of claim 1 , wherein the sample of biocompatible material comprises a multi-layered sheet.5. The medical implant of claim 1 , wherein the sample of biocompatible material is oversized relative to a breast implant.6. The medical implant of claim 1 , wherein the acellular tissue matrix lacks an epithelial basement membrane.7. The medical implant of claim 1 , wherein the acellular tissue matrix is a dermal tissue matrix.8. The medical implant of claim 1 , wherein the acellular tissue matrix comprises a decellularized collagen-containing tissue matrix from a nonhuman animal.9. The medical implant of claim 8 , wherein the nonhuman animal is a pig.10. The medical implant of claim 8 , wherein the nonhuman animal is genetically modified such that tissues in the nonhuman animal lack galactose α-1 claim 8 ,3-galactose epitopes. ...

ARTIFICIAL SKIN

The present invention relates to a method for producing artificial skin, comprising: adding a matrix metalloproteinase inhibitor and a heparanase inhibitor to an artificial skin formation culture medium comprising human epidermal keratinocytes and human dermal fibroblasts, culturing the cells in the artificial skin formation culture medium, and forming artificial skin. 1. Artificial skin , comprising: an epidermal basement membrane containing a continuous lamina densa and anchoring fibers arising from the lamina densa , and a dermis containing collagen fibers; wherein , the epidermal basement membrane and the dermis are securely adhered by bonding of the anchoring fibers arising from the continuous lamina densa present in the epidermal basement membrane to the collagen fibers present in the dermis.2. The artificial skin according to claim 1 , wherein the dermis further contains fibripositors.3. The artificial skin according to claim 1 , wherein elastic fibers are formed in the dermis.4. The artificial skin according to claim 1 , which is produced according to a method for producing artificial skin claim 1 , comprising: adding a matrix metalloproteinase inhibitor and a heparanase inhibitor to an artificial skin formation culture medium comprising human epidermal keratinocytes and human dermal fibroblasts claim 1 , culturing the cells in the artificial skin formation culture medium claim 1 , and forming artificial skin.5. A method for promoting the regeneration and repair of the epidermal basement membrane and/or dermis of a subject in need of the regeneration and repair of the epidermal basement membrane and/or dermis claim 1 , comprising applying a matrix metalloproteinase inhibitor and a heparanase inhibitor to the subject. This application is a Divisional of U.S. application Ser. No. 13/582,199, which is the U.S. National Stage application of PCT/JP2011/050887, filed Jan. 19, 2011, which claims priority from Japanese application JP 2010-048159, filed Mar. 4, 2010. ...

METHOD FOR PREPARING A SUPPLEMENT FROM MESENCHYMAL CELL CULTURES OF WHARTON'S JELLY AND USES OF SAME

A method for preparing a supplement from mesenchymal cell cultures of Wharton's jelly including factors to favor the culture growth of cells from cutaneous system, in vitro, and to methods for producing epidermal, dermal, or cutaneous equivalents, and which may also be used as supplement for the proliferation and activation of autologous fibroblasts for subsequent intradcrmal use. 1. A method for preparing of a supplement to favor the cellular proliferation in vitro of cells from a cutaneous system , the method comprises the steps of:a) cultivating mesenchymal cells of Wharton's jelly in a suitable culture medium with growth factors to reach a suitable confluence;b) harvesting the cultivated cells from step a) and further cultivating the harvested cells in a suitable medium, without growth factors, to form a conditioned medium:c) collecting the conditioned medium from step b);d) repeating steps a) and b), at least once; ande) concentrating the conditioned medium to form a concentrate and sterilizing the concentrate by filtration.2. A supplement comprising growth factors to favor the cellular proliferation in vitro of cells from the cutaneous system prepared in accordance with the method from .3. The supplement in accordance with claim 2 , wherein the supplement is configured for expansion of cutaneous cellular populations or as an addition in culture medium for the same claim 2 , wherein the supplement claim 2 , when in use claim 2 , is diluted in the culture medium to a concentration of between 5% and 50%.4. A method to favor the growth and activation in vitro of cells from cutaneous system characterized in that comprising cultivate such cells from cutaneous system in a culture medium containing the supplement in accordance with .5. The method in accordance with claim 4 , wherein the cells from cutaneous system comprise fibroblasts claim 4 , keratinocytes claim 4 , dendritic cells claim 4 , monocytes or combinations of the same.6. The method in accordance with ...

DEVICES AND METHODS FOR TREATING TISSUES, INCLUDING IRRADIATED TISSUES

The present disclosure provides devices and methods for treating a tissue site. The device and methods can be used to treat tissue that has been irradiated and can include a tissue matrix having the ability to support tissue regeneration and vascularization with cells from the tissue site. 1. A method of treating a tissue site , comprising:selecting a patient having a tissue site that has been irradiated; andimplanting in or near the tissue site a tissue matrix having the ability to support tissue regeneration and vascularization with cells from the tissue site.2. The method of claim 1 , wherein the tissue site is a breast.3. The method of claim 2 , wherein the tissue site is a breast that has undergone a surgical procedure.4. The method of claim 3 , wherein the surgical procedure includes a mastectomy or lumpectomy.5. The method of claim 1 , wherein implanting the tissue matrix includes implanting the tissue matrix around an implant or tissue expander.6. The method of claim 1 , wherein the tissue matrix is an acellular tissue matrix.7. The method of claim 6 , wherein the tissue matrix is a dermal tissue matrix.8. The method of claim 6 , wherein the tissue matrix is a porcine tissue matrix.9. The method of claim 1 , wherein the tissue matrix is in the form of a sheet.10. The method of claim 1 , wherein the tissue has been irradiated with external beam radiation.11. The method of claim 1 , wherein the tissue matrix is in the form of a sheet without mechanically formed fenestrations. This application claims priority under 35 U.S.C. § 119 to U.S. Provisional Application No. 62/774,477, which was filed on Dec. 3, 2018 and is incorporated by reference in its entirety.The present disclosure relates to devices and methods for treating tissue with tissue matrices, including tissue that has been irradiated.The use of acellular tissue matrices such as ALLODERM®, a dermal acellular matrix produced by LIFECELL® CORPORATION (Madison, N.J.), for use in breast procedures has ...

Rapid Preparation of Stem Cell Matrices for Use in Tissue and Organ Treatment and Repair

A rapid method for preparing stem cell and physiologically acceptable matrix compositions for use in tissue and organ repair is described. Compared with previous tissue engineering materials, the stem cell-matrix compositions of the present invention do not require long-term incubation or cultivation in vitro prior to use in in vivo applications. The stem cells can be from numerous sources and may be homogeneous, heterogeneous, autologous, and/or allogeneic in the matrix material. The stem cell-matrix compositions provide point of service utility for the practitioner, wherein the stem cells and matrix can be combined not long before use, thereby alleviating costly and lengthy manufacturing procedures. In addition, the stem cells offer unique structural properties to the matrix composition which improves outcome and healing after use. Use of stem cells obtained from muscle affords contractility to the matrix composition. 127.-. (canceled)28. A method of preparing a vessel like lumen comprising seeding a single layer of small intestine submucosa (SIS) with muscle-derived progenitor cells (MSC) to form a MSC/SIS matrix; folding the MSC/SIS matrix into a vessel-like lumen , thereby preparing a vessel like lumen.29. The method of claim 28 , wherein the MSC are inoculated onto SIS simultaneously with fibrin glue to form the MSC/SIS matrix.30. The method of claim 28 , wherein the MSC are autologous or allogeneic.31. The method of claim 30 , wherein allogeneic cells are from a donor with class I and class II histocompatibility antigen closest matched with a recipient.32. The method of claim 31 , wherein the recipient is on immunosuppressive or immunomodulatory therapy started before claim 31 , during claim 31 , and/or after the matrix is applied or introduced into the recipient.33. The method of claim 32 , wherein the immunosuppressive drug is cyclosporine A.34. A method of repairing a blood vessel comprising introducing to a subject in need thereof a vessel like lumen ...

Surgical grafts for replacing the nipple and areola or damaged epidermis

The present disclosure relates to surgical grafts for replacing nipples and areolas lost to disease or trauma with surgical grafts of decellularized donor nipples and areolas and to placing and recellularizing such grafts. The disclosure further provides methods for decellularizing epidermis. The decellularized epidermis can be used as a protective cover for skin wounds.

ELASTIC TISSUE MATRIX DERIVED HYDROGEL

A tissue-derived hydrogel, as well as methods of making and using such hydrogels, are provided. 1. A tissue filler comprising:an arterial tissue matrix that has been treated with elastase to produce a swollen and softened arterial tissue matrix having a disrupted elastin network and in the form of a moldable putty that will conform to the shape of a space in which it is implanted, and wherein the arterial tissue matrix has an increased malleability after the elastase treatment as compared to the acellular tissue matrix prior to elastase treatment.2. The tissue filler of claim 1 , wherein the arterial tissue matrix is aortic tissue.3. The tissue filler of claim 2 , wherein the aortic tissue is porcine aortic tissue.4. The tissue filler of claim 1 , wherein the arterial tissue matrix is acellular.5. The tissue filler of claim 1 , wherein the elastase-treated arterial tissue matrix expands to a volume that is 200-300% larger than the volume of untreated arterial tissue when placed in an aqueous solution.6. The tissue filler of claim 4 , wherein the arterial tissue matrix can expand after implantation into a tissue to fill a space left by a tissue removal operation.7. The tissue filler of claim 1 , wherein the arterial tissue matrix is treated with elastase at a concentration of between 0.021 and 5.35 units per ml for 5 to 96 hours.8. A method of treating a tissue of the face or neck claim 1 , comprising:implanting a tissue filler into the tissue, wherein the tissue filler comprises an arterial tissue matrix from which some but not all of the elastin has been removed, and wherein the arterial tissue matrix used to prepare the tissue filler has been subjected to at least one round of freezing and thawing followed by removal of at least some elastin from the arterial tissue matrix, and wherein the arterial tissue matrix is not cross-linked prior to implantation.9. The method of claim 8 , wherein the treatment with elastase causes the arterial tissue matrix to ...

COLLAGEN COMPOSITIONS AND USES FOR BIOMATERIAL IMPLANTS

Compositions containing purified collagen biomaterial derived from tissues, for example, insoluble amnion, soluble amnion, soluble chorion of the human placenta, are provided. The collagen compositions can be used to promote wound healing, promote tissue regeneration, prevent or reduce scarring, reduce local inflammation, minimize tissue rejection, promote graft integration. Methods for using the collagen composition as a biomaterial implant for dermal filling, skin grafting, and hair transplantation are also provided. 132-. (canceled)33. A composition for tissue repair or tissue augmentation comprising de-cellularized Type I atelocollagen and Type III atelocollagen in an amount effective to promote wound healing at a site of surgery , injury , or wound relative to an untreated control ,wherein the Type III atelocollagen is between about 30% and 100% by weight, of the total atelocollagen present in the composition.34. The composition of claim 33 , wherein the atelocollagen comprises atelocollagen derived from collagen extracted from human placental tissue without the use of alkaline or detergent.35. The composition of claim 34 , wherein the human placental tissue used for collagen extraction is selected from the group consisting of insoluble amnion claim 34 , soluble amnion claim 34 , soluble chorion claim 34 , and a combination thereof.36. The composition of claim 33 , wherein the atelocollagen comprises collagen-containing claim 33 , de-cellularized human placenta extracellular matrix.37. The composition of claim 33 , wherein the atelocollagen is sterilized.38. The composition of claim 33 , wherein the atelocollagen is cross-linked.39. The composition of further comprising one or more compounds selected from the group consist of antimicrobial agents claim 33 , analgesic agents claim 33 , local anesthetic agents claim 33 , anti-inflammatory agents claim 33 , immunosuppressant agents claim 33 , anti-allergenic agents claim 33 , enzyme cofactors claim 33 , essential ...

Vascular Extracellular Matrix Hydrogel

Provided herein are methods of making an ECM gel from vascular tissue. Also provided herein are ECM compositions prepared from vascular tissue, and methods of use of those compositions, for example in treatment of aneurysms, and for vascularization or re-vascularization. 1. A method of preparing an extracellular matrix (ECM) material , comprising:a. incubating vascular adventitial tissue in a zwitterionic detergent;b. incubating the tissue in Trypsin-EDTA;c. incubating the tissue with an anionic detergent;d. disinfecting the tissue, optionally with peracetic acid, producing a decellularized ECM material;e. lyophilizing the decellularized ECM material;f. comminuting the decellularized ECM material;g. partially or completely solubilizing the decellularized ECM material with an acid protease to produce solubilized ECM; andh. neutralizing the solubilized ECM to produce an ECM pre-gel.2. The method of claim 1 , wherein the decellularized ECM material is not completely digested with the acid protease claim 1 , producing an ECM pre-gel that is able to gel at 37° C. comprising undigested decellularized ECM particles.3. The method of claim 1 , wherein the ECM material is prepared without a dialysis step or a crosslinking step.4. The method of claim 1 , wherein:a. the zwitterionic detergent is CHAPS;b. the anionic detergent is SDS;c. the acid protease is pepsin; ord. the decellularized ECM material is solubilized with an acid protease in a solution having a pH of from 1 to 4, from 1 to 2, or 2.0±0.3.5. The method of claim 1 , comprising dispersing the ECM material in a natural or a synthetic polymer composition claim 1 , optionally wherein the natural or a synthetic polymer composition is one or more of: a second ECM material claim 1 , fibrin claim 1 , collagen claim 1 , polyester (PE) claim 1 , polyurethane (PU) claim 1 , poly(ester urethane) urea (PEUU) claim 1 , poly(ether ester urethane) urea (PEEUU) claim 1 , poly(ester carbonate urethane)urea PECUU) claim 1 , poly( ...

GRAFT MATERIALS FOR SURGICAL BREAST PROCEDURES

Graft materials and devices for surgical breast procedures may include a sheet of biocompatible material and a plurality of fenestrations distributed across a portion of the sheet of biocompatible material. The sheet of biocompatible material can have a first axis and a second axis coincident with the sheet of biocompatible material. The sheet of biocompatible material can also have a first edge that intersects the second axis and a second edge that intersects the second axis. The first axis can be orthogonal to the second axis. The plurality of fenestrations can be distributed across a portion of the sheet of biocompatible material closer to the first edge than the second edge. Other apparatuses and methods are disclosed. 1. A graft for surgical procedures , comprising:a sheet of biocompatible material having a first axis, a second axis, a first edge that intersects the second axis, and a second edge that intersects the second axis; anda plurality of fenestrations distributed across a portion of the sheet of biocompatible material in a plurality of rows, each row forming an arcuate pattern.2. The graft of claim 1 , wherein each fenestration of the plurality of fenestrations is linear.3. The graft of claim 2 , wherein each fenestration of the plurality of fenestrations is parallel to the first axis.4. The graft of claim 2 , wherein each fenestration of the plurality of fenestrations is parallel to the second axis.5. The graft of claim 1 , wherein each fenestration of the plurality of fenestrations is circular.6. The graft of claim 1 , wherein at least one of the first edge and the second edge has a convex curvature.7. The graft of claim 6 , wherein each fenestration of the plurality of fenestrations are linear and parallel to the first edge.8. The graft of claim 1 , wherein the plurality of fenestrations comprises:a first row of fenestrations having a first length; anda second row of fenestrations having a second length;wherein the second length is greater than the ...

TRANSGLUTAMINASE TREATED PRODUCTS

The present application relates to use of transglutaminases to treat various products, including medical devices such as tissue grafts, tissue matrices or other tissue-derived materials, and synthetics. The transglutaminases can be applied to the medical devices to provide advantages such as adhesion resistance or abrasion resistance. 1. A method of treatment , comprising:selecting a medical device comprising an implant main body portion comprising a collagen-containing tissue matrix having a surface region that has been treated with a transglutaminase coating, and wherein the treated surface region provides at least one of an anti-adhesion or anti-abrasion property to the tissue matrix; andimplanting the medical device into or on an anatomic site.2. The method of claim 1 , wherein the implant main body portion comprises a sheet of collagen-containing tissue matrix.3. The method of claim 1 , wherein the collagen-containing tissue matrix comprises an acellular tissue matrix.4. The method of claim 1 , wherein the collagen-containing tissue matrix is produced from tissue derived from a tissue selected from fascia claim 1 , adipose claim 1 , pericardial tissue claim 1 , dura claim 1 , umbilical cord tissue claim 1 , placental tissue claim 1 , cardiac valve tissue claim 1 , ligament tissue claim 1 , tendon tissue claim 1 , arterial tissue claim 1 , venous tissue claim 1 , neural connective tissue claim 1 , urinary bladder tissue claim 1 , ureter tissue claim 1 , muscle claim 1 , and intestinal tissue.5. The method of claim 1 , wherein the collagen-containing tissue matrix is produced from tissue derived from skin.6. The method of claim 1 , wherein the collagen-containing tissue matrix comprises a dermal tissue matrix.7. The method of claim 1 , wherein the medical device is dry.8. The method of claim 1 , wherein the medical device further comprises a synthetic substrate claim 1 , wherein the collagen-containing tissue matrix is in contact with the synthetic substrate.9. ...

SURGICAL GRAFTS FOR REPLACING THE NIPPLE AND AREOLA OR DAMAGED EPIDERMIS

The present disclosure relates to surgical grafts for replacing nipples and areolas lost to disease or trauma with surgical grafts of decellularized donor nipples and areolas and to placing and recellularizing such grafts. The disclosure further provides methods for decellularizing epidermis. The decellularized epidermis can be used as a protective cover for skin wounds. 138-. (canceled)39. A surgical graft for grafting to a patient , said graft comprising a decellularized nipple , a decellularized areola , or a decellularized nipple attached to a decellularized areola , which decellularized nipple , areola or nipple attached to an areola substantially retains at least one cell adhesion molecule selected from the group consisting of laminin , elastin , fibronectin , and collagen VI , wherein said graft has been at least partially repopulated with cells derived from a healthy nipple , areola or nipple and areola from said patient.40. The surgical graft of claim 39 , wherein said cells derived from said patient are keratinocytes.41. A method of making a surgical graft to replace a body part on a patient claim 39 , said body part having an epidermis and a dermis claim 39 , and selected from the group consisting of a nipple claim 39 , an areola claim 39 , and a nipple attached to an areola claim 39 , said method comprising:(a) obtaining a donor nipple, an areola, or a nipple attached to an areola, and,(b) decellularizing said nipple, areola, or nipple attached to an areola to decellularize cells of the epidermis and cells of the dermis, while substantially retaining at least one cell adhesion molecule selected from the group consisting of laminin, fibronectin, and collagen VI,(c), incubating said decellularized body part with cells from a healthy nipple, areola, or both nipple and areola, which cells are derived from said patient, under conditions conducive to repopulating said body part with said cells from said healthy nipple, areola, or nipple and areola derived from ...

Decellularization Method and System and Decellularized Tissue Formed Thereby

Systems and methods that establish a pressure differential across a tissue wail to encourage complete decellularization of the wall are described. The methods can be utilized for decellularization of blood vessel tissue including heart valves and surrounding tissues. The methods and systems can essentially completely decellularize the treated tissue segments. Systems can be utilized to decellularize one or multiple tissue segments at a single time. 1. A method for decellularizing a tissue segment , the tissue segment including a lumen and a tissue wall surrounding the lumen , the tissue wall having an interior surface facing the lumen and an exterior surface that is opposite the interior surface the method comprising:contacting the interior surface of the tissue wall with a first decellularization solution;contacting the exterior surface of the tissue wall with a second decellularization solution;establishing a pressure differential across the tissue wall from the interior surface to the exterior surface for a period of time of about 1 minute or more, the pressure differential being from about 15 mmHg to about 150 mmHg;following the period of time, decreasing the pressure differential to a lower pressure differential across the tissue wall that is about 15 mmHg or less.2. The method of claim 1 , further comprising repeating the method one or more times.3. The method of claim 1 , wherein the period of time is about 5 minutes or less.4. The method of claim 1 , wherein the pressure differential is decreased to zero.5. The method of claim 1 , wherein the tissue segment is a vascular segment.6. The method of claim 1 , wherein the tissue segment comprises a heart valve in the lumen.7. The method of claim 1 , wherein the tissue segment comprises muscle tissue.8. The method of claim 1 , wherein the tissue segment comprises an aortic root.9. The method of claim 1 , wherein following the decrease in the pressure differential claim 1 , the tissue is held at the lower pressure ...

Tissue Prostheses for Repairing, Reconstructing and Replacing Damaged or Diseased Biological Structures and Associated Tissue

Non-antigenic, resilient, bioremodelable, biocompatible tissue prostheses that can be engineered into a variety of shapes and used to repair, augment, reconstruct or replace damaged or diseased biological structures and associated tissue.

CARDIAC OR VASCULAR TISSUE SPHEROID

Provided is a method for producing a cardiac tissue spheroid or vascular tissue spheroid formed from a mixture of a myocardial cell or smooth muscle cell and at least one type of cell selected from a vascular endothelial cell and fibroblast, and a three dimensional cardiac tissue structure or three dimensional vascular tissue structure which are characterized by combining or laminating said spheroid. 1. A cardiac tissue spheroid formed from a mixture of cardiomyocytes and at least one type of cells selected from vascular endothelial cells and fibroblasts.2. The cardiac tissue spheroid according to claim 1 , formed from a mixture of cardiomyocytes claim 1 , vascular endothelial cells and fibroblasts.3. The cardiac tissue spheroid according to claim 2 , wherein the mixture ratio of the cardiomyocytes claim 2 , the vascular endothelial cells and the fibroblasts is such that the vascular endothelial cells are 10-60 and the fibroblasts are 10-60 to the cardiomyocytes of 100.4. A cardiac tissue spheroid obtained by fusing a spheroid formed from cardiomyocytes and a spheroid formed from at least one type of cells selected from vascular endothelial cells and fibroblasts.5. The cardiac tissue spheroid according to obtained by fusing a spheroid formed from cardiomyocytes claim 4 , a spheroid formed from vascular endothelial cells and a spheroid formed from fibroblasts.6. The cardiac tissue spheroid according to claim 5 , wherein the abundance ratio of the spheroid derived from cardiomyocytes claim 5 , the spheroid derived from vascular endothelial cells and the spheroid derived from fibroblasts is such that the spheroid derived from vascular endothelial cells is 10-60 and the spheroid derived from fibroblasts is 10-60 to the spheroid derived from cardiomyocytes of 100.7. A method for producing a three-dimensional cardiac tissue structure claim 5 , comprising the step of compounding or laminating the cardiac tissue spheroids according to or .8. The method according to claim 7 ...

HIGH SPEED 3D PRINTING SYSTEM FOR WOUND AND TISSUE REPLACEMENT

A method or apparatus for creating a three-dimensional tissue construct of a desired shape for repair or replacement of a portion of an organism. The method may comprise injecting at least one biomaterial in a three-dimensional pattern into a first material such that the at least one biomaterial is held in the desired shape of the tissue construct by the first material. The apparatus may comprise an injector configured to inject at least one biomaterial in a three-dimensional pattern into a first material such that the at least one biomaterial is held in the desired shape of the tissue construct by the first material. The first material may comprise a yield stress material, which may be a material exhibiting Herschel-Bulkley behavior. The tissue construct may have a smallest feature size of ten micrometers or less. 1. A method for creating a three-dimensional tissue construct of a desired shape for repair or replacement of tissue of a tissue cavity of an organism , the method comprising:injecting at least one biomaterial in a three-dimensional pattern into a first material such that the at least one biomaterial is held in the desired shape of the tissue construct by the first material.2. The method of claim 1 , further comprising:removing the injected at least one biomaterial from the first material.3. The method of claim 2 , wherein removing the injected at least one biomaterial from the first material comprises washing away the first material.4. The method of claim 2 , further comprising:inserting the tissue construct into the tissue cavity of the organism.5. The method of claim 2 , further comprising:attaching the tissue construct to the organism at the tissue cavity.6. The method of claim 1 , wherein:injecting the at least one biomaterial comprises injecting the at least one biomaterial such that the tissue construct has a smallest feature size of less than 1 millimeter7. The method of claim 6 , wherein injecting the at least one biomaterial comprises injecting ...

BREAST TREATMENT DEVICE

The present disclosure provides devices and methods for treating the breast. The devices can include an acellular tissue matrix having a predefined shape. The shape can include a first edge with an S-shaped configuration and a second arcuate-shaped edge. The shape alternatively can include a first concave edge and a second convex edge. 127-. (canceled)28. A breast treatment device , comprising:a sheet of acellular tissue matrix, wherein the sheet of acellular tissue matrix comprises a flexible sheet with a top surface, a bottom surface, and a peripheral border, and wherein the peripheral border comprises a first edge having a concave shape, and a convex-shaped second edge.29. The device of claim 28 , wherein the first edge and second edge meet at a first end of the device and at a second end of the device.30. The device of claim 29 , wherein the first end of the device comprises a first pointed tip.31. The device of claim 30 , wherein the second end of the device comprises a second pointed tip.32. The device of claim 29 , wherein the second end of the device comprises a rounded edge.33. The device of claim 28 , wherein the tissue matrix comprises a tissue matrix derived from a human tissue.34. The device of claim 28 , wherein the tissue matrix comprises a tissue matrix derived from porcine tissue.35. The device of claim 28 , wherein the tissue matrix comprises a dermal tissue matrix.36. The device of claim 35 , wherein the dermal tissue matrix further comprises an epithelial basement membrane on the top surface of the tissue matrix.37. A method of treating a breast claim 35 , comprising:identifying an anatomic site within a breast;selecting a breast treatment device comprising a sheet of acellular tissue matrix, wherein the sheet of acellular tissue matrix comprises a flexible sheet with a top surface, a bottom surface, and a peripheral border, and wherein the peripheral border comprises a first edge having a concave shape, and a convex-shaped second edge; ...

POLYMER-PERMEATED GRAFTS AND METHODS OF MAKING AND USING THE SAME

This invention is directed to polymer-permeated grafts and methods of making and using the same. 1. An polymer-permeated graft for in vivo use in a subject comprising a tissue substantially free of cells , wherein the decellularized tissue is substantially free of water and is permeated with polymer , and wherein the polymer is substantially uniformly distributed in said tissue.2. The graft of claim 1 , wherein the graft comprises less than about 50% polymer.3. The graft of claim 2 , wherein the graft comprises about 0.1% to about 30% polymer.4. The graft of claim 1 , wherein the tissue comprises a dermal tissue and/or an epidermal tissue.5. The graft of claim 1 , wherein the tissue comprises an organ claim 1 , a muscle claim 1 , a ligament claim 1 , a bone claim 1 , a nipple claim 1 , areola claim 1 , a nipple attached to an areola claim 1 , a lip claim 1 , skin claim 1 , a tendon claim 1 , an aorta claim 1 , a blood vessel.6. The graft of claim 1 , wherein the tissue substantially retains at least one matrix molecule.7. The graft of claim 1 , wherein the matrix molecule comprises a component of the extracellular matrix.8. The graft of claim 1 , wherein the matrix molecule comprises laminin claim 1 , elastin claim 1 , fibronectin claim 1 , collagen claim 1 , or a combination thereof.9. The graft of claim 8 , wherein the collagen comprises a Type I collagen claim 8 , a Type III collagen claim 8 , a Type IV collagen claim 8 , a Type VI collagen claim 8 , or a combination thereof.10. The graft of claim 1 , wherein the tissue is substantially free of skin claim 1 , fat and/or fibrous tissue.11. The graft of claim 1 , wherein the polymer comprises a colored polymer.12. The graft of claim 11 , wherein the colored polymer comprises melanin claim 11 , a dye claim 11 , or a combination thereof.13. The graft of claim 1 , wherein the polymer comprises a natural polymer and/or a synthetic polymer.14. The graft of claim 1 , wherein the natural polymer comprises alginate or ...

INTESTINAL TISSUE ENHANCED WITH THERAPEUTIC SALTS

The present invention is product and method for treating wounds, or enhancing wound healing, by contacting the wound with biomaterial or tissue that has been treated with a boron and copper composition. 1. A method of treating biomaterial comprising contacting the biomaterial with a treatment composition comprising a source of boron ions and a source of copper ions.2. The method of wherein the source of boron ions comprises up to about 80% of the composition.3. The method of wherein the source of copper ions comprises up to about 5% of the composition.4. The method of wherein the treatment composition further comprises one or more of the following ingredients: a source of calcium; a source of potassium; a source a magnesium; a source of sodium; a source of phosphorus; ionic forms or any of the above; oxide forms of any of the above; a source of strontium; a source of zinc; a source of iron; ionic forms of strontium claim 1 , zinc claim 1 , or iron; oxide forms of strontium claim 1 , zinc claim 1 , or iron; and any of the ingredients listed above alone or in any combination.5. The method of wherein the treatment composition comprises a boron oxide and a copper oxide; and further comprises at least one of an oxide of calcium claim 1 , potassium claim 1 , magnesium claim 1 , sodium claim 1 , or phosphorus.6. The method of wherein the treatment composition is an electrolyte composition.7. The method of wherein the biomaterial is selected from the group consisting of an ECM-containing material; submucosa tissues; renal capsule membrane; amnion; dura matter; pericardium; serosa; and peritoneum or basement membrane.8. The method of wherein the biomaterial is intestinal submucosa.9. The method of wherein the biomaterial is small intestine submucosa.10. The method of wherein the biomaterial is derived from an animal or human source.11. The method of wherein the biomaterial is contacted with an antimicrobial composition prior to contact with the treatment composition.12. A ...

POLAND SYNDROME AND METHODS OF TREATMENT

This invention is directed to grafts and compositions and methods of using the same to treat Poland Syndrome. 1. A composition consisting essentially of decellularized dermis and/or decellularized epidermis , wherein the dermis and/or epidermis retain(s) at least one matrix molecule selected from the group consisting of laminin , elastin , fibronectin , and collagen; and wherein the decellularized dermis and/or decellularized epidermis further comprises an exogenous seeded cell.2. The composition of claim 1 , wherein the dermis and/or epidermis comprises a decellularized nipple claim 1 , a decellularized areola claim 1 , or a decellularized nipple attached to a decellularized areola.3. The composition of claim 1 , wherein the exogenous seeded cell comprises a keratinocyte claim 1 , a melanocyte claim 1 , a nerve cell claim 1 , or a combination thereof.4. The composition of claim 1 , wherein the collagen comprises a Type I collagen claim 1 , a Type III collagen claim 1 , a Type IV collagen claim 1 , a Type VI collagen claim 1 , or a combination thereof.5. The composition of further comprising a cross-linking agent.6. The composition of claim 5 , wherein the cross-linking agent comprises glutaraldehyde claim 5 , genipin claim 5 , or a combination thereof7. An implantable surgical graft comprising the composition of any one of -.14. The method of claim 5 , claim 5 , claim 5 , claim 5 , claim 5 , or claim 5 , wherein the exogenous seeded cell comprises a keratinocyte claim 5 , a melanocyte claim 5 , a nerve cell claim 5 , or a combination thereof.15. The method of claim 14 , wherein the seeded nerve cell comprises seeded neurospheres or seeded neuronal cells.16. The method of claim 14 , claim 14 , claim 14 , claim 14 , claim 14 , or claim 14 , wherein the collagen comprises a Type I collagen claim 14 , a Type III collagen claim 14 , a Type IV collagen claim 14 , a Type VI collagen claim 14 , or a combination thereof. This application claims priority from U.S. ...

BIOLOGICAL VALVE FOR VENOUS INSUFFICIENCY

A bioprosthetic valve for repairing a deep venous insufficiency in a subject includes a single leaflet from a xenogeneic heart valve attached at natural margins of attachment to a patch of valve wall tissue. The patch may extend axially above and below the leaflet and circumferentially on either side of the leaflet to provide a region for attaching the patch to a fenestration in a host vein. A bioprosthetic valve may be manufactured by excising a portion of a xenogeneic heart valve including a single leaflet and contiguous wall tissue, and may further comprise shaving off excess leaflet tissue from adjacent leaflets. A method of replacing a malfunctioning venous valve in a subject includes providing a bioprosthetic valve as described above and inserting it to the host vein. 1. A method of providing a valve function in a host vein of a subject , the method comprising:providing a biological valve comprising a single leaflet xenogeneic heart valve tissue;attaching the single leaflet xenogeneic heart valve tissue at natural margins to a patch of contiguous tissue from the xenogeneic heart valve;inserting said replacement biological valve into said host vein at a patch site in the host vein; andsurrounding the host vein at the patch site with a tube attached to the patch.2. The method of claim 1 , further comprising creating a fenestration in the host vein claim 1 , the fenestration having a shape generally corresponding to the patch.3. The method of claim 1 , wherein the tube is created from a biological material.4. The method of claim 1 , wherein the tube is created from a nonbiological material.5. The method of claim 1 , wherein the leaflet need not completely obstruct the host vein.6. The method of claim 2 , further comprising attaching the replacement biological valve to the host vein at the fenestration.7. The method of claim 1 , further comprising removing at least one leaflet from the malfunctioning valve of the host vein.8. The method of claim 1 , wherein the ...

METHOD OF TREATING OR PREVENTING HERNIA FORMATION

A method of preventing or reducing the occurrence and/or development of a hernia within a subject at risk of developing a hernia includes implanting a graft material in contact with an opening in an abdominal wall. The graft material promotes healing of the abdominal wall and includes placental or placental derived tissue. 1. A method of repairing a hernia in a subject , comprising:obtaining a graft material; andimplanting the graft material in the subject, wherein the graft material is implanted in contact with an opening in the abdominal wall, and wherein the graft material comprises placental tissue and promotes healing of the abdominal wall opening.2. The method of claim 1 , wherein implanting the graft material includes aligning the graft material with the opening in the abdominal wall.3. The method of claim 1 , wherein the opening comprises a surgical incision.4. The method of claim 1 , wherein the opening comprises debrided fascia.5. The method of claim 1 , wherein the graft material promotes healing of the abdominal fascial edges.6. The method of claim 1 , wherein implanting the graft material does not actively affix the graft material to the abdominal wall.7. The method of claim 1 , wherein implanting the graft material comprises anchoring the graft material to the abdominal wall by pressure claim 1 , an adhesive claim 1 , a clip claim 1 , a tack claim 1 , a suture claim 1 , a staple claim 1 , or a screw.8. The method of claim 1 , wherein implanting the graft material comprises implanting the graft material over or ventral to the abdominal wall opening.9. The method of claim 1 , wherein implanting the graft material comprises implanting the graft material under or dorsal to the abdominal wall opening.10. The method of claim 1 , further comprising substantially or completely closing the abdominal wall opening prior to or after implanting the graft material.11. The method of claim 10 , wherein the abdominal wall opening is closed with synthetic mesh or ...

Seamless Tubular Extracellular Matrix Prosthetic Valve and Method for Forming Same

A seamless prosthetic valve having an outer abluminal surface, a triple walled intermediate portion, and at least one valve leaflet that is configured to selectively restrict fluid flow through the valve, the valve leaflet being formed by suturing the triple walled intermediate portion at a first commissure connection point. 1. A seamless prosthetic valve , comprising:a continuous tubular structure having an inner lumen, outer abluminal surface, first and second ends, a triple walled intermediate portion, and first and second valve leaflets, said tubular structure comprising extracellular matrix (ECM) from a mammalian tissue source,said first and second valve leaflets being configured to transition from a first position, wherein fluid flow in a first direction through said seamless prosthetic valve is unrestricted, to a second position, wherein fluid flow in a second direction through said seamless prosthetic valve is restricted,said triple walled intermediate portion being formed by everting said first end of said tubular structure over said tubular structure to form a double walled first end and a doubled wall portion proximal to and extending from said double walled end, and reverting said first end of said tubular structure over said double walled end of said tubular structure,said first and second valve leaflets being formed in said tubular structure lumen by suturing said triple walled intermediate portion at two commissure connection points, wherein said first and second valve leaflets comprise two restrained regions and two unrestrained regions.2. The prosthetic valve of claim 1 , wherein said triple walled intermediate portion is sutured at three commissure connection points claim 1 , wherein third claim 1 , fourth and fifth valve leaflets are formed claim 1 , and wherein said third claim 1 , fourth and fifth valve leaflets comprise three restrained regions and three unrestrained regions.3. The prosthetic valve of claim 1 , wherein said ECM comprises small ...

DEPOTS AND ENCASEMENT STRUCTURES FOR IMPLANTABLE DEVICES

Encasement structures and methods of customizing patient drug delivery profiles using an encasement structure are described herein. Encasement structures can be configured to receive an implantable medical device and physicians can implant the medical devices within the encasement structures. Encasement structures can include at least one sheet of a bioscaffold material and one or more depots. depots can be configured to release an active agent, such as an antibiotic, to the medical device within the encasement structure and/or the surrounding tissue. The depots can be insertable into or integrated with the at least one sheet of bioscaffold material. 142-. (canceled)43. An encasement structure comprising:at least one sheet comprising a bioscaffold material, the at least one sheet configured to define an internal region that is sized and shaped to hold an implantable medical device therein; andone or more depots associated with the at least one sheet,wherein the one or more depots comprise an effective amount of one or more active agents and a bioabsorbable material, and are configured to release the one or more active agents over a period of time.44. The encasement structure of claim 43 , wherein the bioscaffold material comprises decellularized extracellular matrix (ECM).45. The encasement structure of claim 44 , wherein the decellularized extracellular matrix is acellular.46. The encasement structure according to claim 44 , wherein the ECM is derived from mammalian tissue.47. The encasement structure according to claim 44 , wherein the ECM is derived from one or more of small intestine submucosa (SIS); urinary bladder submucosa (UBS); stomach submucosa (SS); central nervous system tissue; other tissue of mesodermal origin; dermal tissue; subcutaneous tissue; gastrointestinal tissue; tissue surrounding growing bone; placental tissue; omentum tissue; cardiac tissue; kidney tissue; pancreatic tissue; lung tissue; and any combination thereof.48. The encasement ...

PIXEL ARRAY MEDICAL SYSTEMS, DEVICES AND METHODS

Systems, instruments, methods, and compositions are described involving removing a portion of the epidermis within a donor site on a subject, and harvesting dermal plugs within the donor site. An injectable filler is formed by mincing the dermal plugs. The injectable filler is configured for injecting into a recipient site on the subject. 198-. (canceled)99. A device comprising:a carrier configured to removeably couple to a chamber, wherein the carrier includes a drive shaft configured to rotate; anda cannula assembly configured to removeably couple to the chamber and to the drive shaft, wherein the cannula assembly includes at least one cannula configured to be rotated by the drive shaft and including a sharpened distal end forming a cylindrical scalpel configured to incise skin pixels, wherein the cannula is coupled to the chamber and configured to pass the skin pixels.100. The device of claim 99 , wherein the chamber comprises a first end and a second end claim 99 , wherein the carrier is configured to removeably couple to the first end.101. The device of claim 100 , wherein the cannula assembly is configured to removeably couple to the second end.102. The device of claim 101 , wherein the chamber is configured as a collection chamber to collect the skin pixels.103. The device of claim 102 , wherein the cannula assembly includes a vacuum port configured to couple the at least one cannula to a vacuum source.104. The device of claim 103 , wherein the chamber is configured to include a vacuum fitting claim 103 , wherein the vacuum fitting is removeable and configured to couple the vacuum port to the vacuum source.105. The device of claim 104 , wherein the vacuum is configured to pull the skin pixels into the chamber via the shaft of the at least one cannula.106. The device of claim 102 , comprising a first end cap configured to removeably couple to the second end of the chamber.107. The device of claim 106 , wherein the first end cap includes a depth guide ...

Prosthetic Valves And Related Inventions

This invention relates to the design and function of a compressible valve replacement prosthesis, collared or uncollared, which can be deployed into a beating heart without extracorporeal circulation using a transcatheter delivery system. The design as discussed focuses on the deployment of a device via a minimally invasive fashion and by way of example considers a minimally invasive surgical procedure preferably utilizing the intercostal or subxyphoid space for valve introduction. In order to accomplish this, the valve is formed in such a manner that it can be compressed to fit within a delivery system and secondarily ejected from the delivery system into the annulus of a target valve such as a mitral valve or tricuspid valve.

BIOLOGICAL MATERIAL WITH COMPOSITE EXTRACELLULAR MATRIX COMPONENTS

A biological material with composite extracellular matrix component, in which decellularized small intestinal submucosa (SIS) is treated as the interlayer and decellularized urinary bladder matrix (UBM) is treated as superior and inferior surface layers. The interlayer is totally encapsulated by the mentioned superior and inferior surface layers, forming a sandwich structure with advantages of integrating UBM and SIS to have high bioactivity with bionic structure, UBM isolates the immunogenicity of SIS and direct contact with host tissue, and after implantation the basic type of inflammatory interaction in the host-implant marginal zone is the same as that of pure UBM, with high biocompatibility; effective endotoxin removal optimize the biosafety of the material after implantation; feasibility for industrial large-scale production; the stiffness of the material can be maintained even after hydration, with good handling feel and fit condition, beneficial for the suture fixation and also shorten the fixation or surgery time. 1. A biological material with composite extracellular matrix components , comprising:an interlayer containing a decellularized small intestinal submucosa (SIS);a superior surface layer containing a decellularized urinary bladder matrix (UBM);an inferior surface layer containing a UBM;wherein the superior surface layer and the inferior surface layer encapsulated completely the interlayer to form a sandwich structure;wherein the thickness of the superior surface layer is 0.05 mm-0.2 mm;wherein the thickness of the inferior surface layer is 0.05 mm-0.2 mm;wherein the SIS were processed for effective endotoxin removal;wherein the effective endotoxin removal process is as follows: the SIS is treated with lipid reduction process to reduce the lipid content to less than 2% and subsequently treated with an alkali solution.2. A biological material with composite extracellular matrix components of claim 1 , wherein the bending length of the biological ...

Serous membrane for ocular surface disorders

A new method for the treatment of ocular disease and injury are provided. 1. A method for inducing restoration of diseased or defective ocular tissues , said method COMPRISING: applying a transparent biocompatible implant , the porcine small intestinal serosa (or serous membrane) as graft/patch in direct contact with the injured ocular surface.2. The method of wherein said method COMPRISING the utilization of the porcine small intestinal serosa (or serous membrane) in human or veterinary ophthalmology claim 1 , in eyes as overlay graft (to facilitate epithelialization) claim 1 , inlay graft (to replacing the deficient stromal connective tissue as well as stimulating re-epithelialization) or combined inlay and overlay grafts to promote and protect epithelial recovery.3. The method of wherein said method COMPRISING the utilization of the porcine small intestinal serosa (or serous membrane) claim 2 , for inducing restoration claim 2 , remodeling claim 2 , and repair of a tissue in a variety of injuries or conditions in the cornea claim 2 , the conjunctiva claim 2 , and/or the eyelid due to trauma claim 2 , diseases claim 2 , or surgery.4. The method of wherein said restoration claim 3 , remodeling claim 3 , or repair of the ocular surface COMPRISES the induction of connective and epithelial tissue repair at said tissue defect site. Not ApplicableNot ApplicableNot ApplicableNot ApplicableNot ApplicableThis invention, in the field of ophthalmology, relates to a novel clinical application in ocular surface disorders of the porcine small intestinal serosa (or serous membrane), prepared with new processes.In the field of ophthalmology, the regeneration of a healthy ocular surface epithelium after traumatic injury or reconstruction techniques is one of the most difficult challenges for repair, and sometimes arise structural changes (vascularization and scarring, epithelial erosions or ulcerations occur among others) and/or functional (corneal opacity or lack of transparency) ...

METHODS OF CONDITIONING SHEET BIOPROSTHETIC TISSUE

Methods for the conditioning of bioprosthetic material employ bovine pericardial membrane. A laser directed at the fibrous surface of the membrane and moved relative thereto reduces the thickness of the membrane to a specific uniform thickness and smoothes the surface. The wavelength, power and pulse rate of the laser are selected which will smooth the fibrous surface as well as ablate the surface to the appropriate thickness. Alternatively, a dermatome is used to remove a layer of material from the fibrous surface of the membrane. Thinning may also employ compression. Stepwise compression with cross-linking to stabilize the membrane is used to avoid damaging the membrane through inelastic compression. Rather, the membrane is bound in the elastic compressed state through addition cross-linking. The foregoing several thinning techniques may be employed together to achieve strong thin membranes. 1. A method for preparing a bioprosthetic tissue membrane material , comprising:subjecting a collagenous tissue membrane to a glycerin-based treatment solution; andremoving at least a portion of material from a surface of the collagenous tissue membrane by ablating the collagenous tissue membrane with a laser, the surface of the collagenous tissue membrane having a smoothness;wherein the removing increases the smoothness of the surface of the collagenous tissue membrane.2. The method of claim 1 , wherein the collagenous tissue membrane is bovine pericardial tissue.3. The method of claim 2 , wherein the bovine pericardial tissue has a fibrous side and a smooth side.4. The method of claim 3 , wherein the surface of the collagenous tissue membrane is the fibrous side.5. The method of claim 1 , further comprising cross-linking the collagenous tissue membrane before the subjecting.6. The method of claim 1 , wherein the collagenous tissue membrane has opposite sides and a non-uniform thickness.7. The method of claim 6 , further comprising topographically mapping the collagenous ...

ALLOGENEIC MICROVASCULAR TISSUE FOR SOFT TISSUE TREATMENTS

Disclosed are products and methods for treating soft tissue injuries. The provided methods include the production of processed or cryopreserved microvascular tissue. Also provided are products and methods of using processed or cryopreserved microvascular tissue for the treatment of soft tissue injuries. 1. A method for repair or regeneration of a tissue selected from the group consisting of tendon , ligament , and skin , said method comprising applying a plurality of uncultured allogeneic stem or progenitor cells to said tissue and thereby effecting repair or regeneration of the tissue as compared to a control tissue to which uncultured allogeneic stem or progenitor cells are not applied.2. The method of claim 1 , wherein said plurality of uncultured allogeneic stem or progenitor cells are included in a processed or cryopreserved microvascular tissue.3. The method of claim 1 , wherein said plurality of uncultured allogeneic stem or progenitor cells comprise xenogeneic cells.4. The method of claim 1 , wherein said plurality of uncultured allogeneic stem or progenitor cells is less than 50% viable.5. The method of claim 1 , wherein said plurality of uncultured allogeneic stem or progenitor cells contains substantially no viable cells.6. A composition comprising a plurality of uncultured stem or progenitor cells formulated for implantation into an allogeneic or xenogeneic recipient claim 1 , said composition having tissue healing activity and comprising no bone or bone-derived matrix.7. The composition of claim 6 , wherein said plurality of uncultured allogeneic stem or progenitor cells are included in a processed or cryopreserved microvascular tissue.8. The composition of claim 6 , wherein said plurality of uncultured allogeneic stem or progenitor cells is less than 50% viable.9. The composition of claim 6 , wherein said plurality of uncultured stem or progenitor cells contains substantially no viable cells.10. The composition of claim 6 , wherein said composition is ...

ARTIFICIAL TISSUE PROGENITOR AND METHOD FOR PREPARING THE SAME

The invention relates to the technical filed of tissue engineering and 3D printing, particularly relates to an artificial tissue progenitor and a method for preparing the same. In particular, the invention relates to an artificial tissue progenitor comprising a solid support and a plurality of microcapsules, wherein at least one microcapsule is attached to the solid support, and the microcapsule comprises a cell and a biocompatible material encapsulating the cell, to a method for preparing the artificial tissue progenitor, to a kit and a package useful for preparing the artificial tissue progenitor, to an artificial tissue obtained by culturing the artificial tissue progenitor, such as an artificial lumen, to a lumen implant or a lumen model containing the artificial tissue progenitor or the artificial lumen, to use of the artificial tissue progenitor in the manufacture of an artificial tissue, a lumen implant or a lumen model, and to use of the artificial tissue in the manufacture of a lumen implant or lumen model. 1. An artificial tissue progenitor comprising a solid support and a plurality of microcapsules , wherein at least one microcapsule is attached to the solid support , and the microcapsule comprises a cell and a biocompatible material encapsulating the cell; the artificial tissue progenitor is a blood vessel progenitor.2. The artificial tissue progenitor of claim 1 , having one or more features selected from the following:(1) the artificial tissue progenitor is tubular;(2) the microcapsules each independently have a size of 100-500 μm;(3) the microcapsules are each independently spherical;(4) the microcapsule is in a gel state;(5) the microcapsules contain undifferentiated cells;(6) the cells in the microcapsules are adipose-derived mesenchymal stem cells;(7) the cells are obtained from a human, a monkey, a pig or a dog; and(8) the cells are derived from adipose tissue.3. The artificial tissue progenitor according to claim 1 , wherein the biocompatible ...

Prosthetic Valves And Related Inventions

This invention relates to the design and function of a compressible valve replacement prosthesis, collared or uncollared, which can be deployed into a beating heart without extracorporeal circulation using a transcatheter delivery system. The design as discussed focuses on the deployment of a device via a minimally invasive fashion and by way of example considers a minimally invasive surgical procedure preferably utilizing the intercostal or subxyphoid space for valve introduction. In order to accomplish this, the valve is formed in such a manner that it can be compressed to fit within a delivery system and secondarily ejected from the delivery system into the annulus of a target valve such as a mitral valve or tricuspid valve.

Bone Augmentation Utilizing Muscle-Derived Progenitor Compositions in Biocompatible Matrix, and Treatments Thereof

The present invention provides muscle-derived progenitor cells that show long-term survival following transplantation into body tissues and which can augment non-soft tissue following introduction (e.g. via injection, transplantation, or implantation) into a site of non-soft tissue (e.g. bone) when combined with a biocompatible matrix, preferably SIS. The invention further provides methods of using compositions comprising muscle-derived progenitor cells with a biocompatible matrix for the augmentation and bulking of mammalian, including human, bone tissues in the treatment of various functional conditions, including osteoporosis, Paget's Disease, osteogenesis imperfecta, bone fracture, osteomalacia, decrease in bone trabecular strength, decrease in bone cortical strength and decrease in bone density with old age. 134-. (canceled)35. A method of accelerating formation of mineralized matrix on small intestine submucosa (SIS) sheets and/or scaffolds comprising seeding SIS disks with human muscle-derived progenitor cells (hMDCs) in an osteogenic medium to form SIS sheets , wherein the mineralization is achieved within 7 days; wherein the mineralization is accelerated compared to SIS scaffolds not seeded with hMDCs (empty SIS) cultured in the osteogenic medium.36. The method of claim 35 , wherein the hMDCs seeded SIS disks are incubated for 28 days in the osteogenic medium.37. The method of claim 35 , wherein volume of the mineralized matrix is progressively increased as observed at 7 days claim 35 , at 10 days claim 35 , at 14 days claim 35 , at 21 days claim 35 , and at 28 days.38. The method of claim 37 , wherein density of the mineralized matrix in SIS scaffolds with hMDCs cultivated in the osteogenic medium is about 222 mm HA/ccm at 7 days.39. The method of claim 37 , wherein density of the mineralized matrix in SIS scaffolds with hMDCs cultivated in the osteogenic medium is about 200 mm HA/ccm at 28 days.40. The method of claim 35 , wherein the empty SIS scaffolds ...

BIOPROSTHETIC TISSUE HAVING A REDUCED PROPENSITY FOR IN VIVO CALCIFICATION

A bioprosthetic tissue having a reduced propensity to calcify in vivo, the bioprosthetic tissue. The bioprosthetic tissue comprises an aldehyde cross-linked and stressed bioprosthetic tissue comprising exposed calcium, phosphate or immunogenic binding sites that have been reacted with a calcification mitigant. The bioprosthetic tissue has a reduced propensity to calcify in vivo as compared to aldehyde cross-linked bioprosthetic tissue that has not been stressed and reacted with the calcification mitigant. 1. A method of treating a cross-linked bioprosthetic tissue to reduce in vivo calcification , the method comprising:immersing a cross-linked bioprosthetic tissue in a solution comprising a calcification mitigant; andstressing the cross-linked bioprosthetic tissue by subjecting the cross-linked bioprosthetic tissue to pulsed fluid flow in the solution comprising the calcification mitigant;wherein the stressing produces localized micro collagen fibril damage at sites of flexion and acid binding sites; andwherein the calcification mitigant couples with the acid binding sites to produce capped acid binding sites.2. The method of claim 1 , wherein the calcification mitigant is one or more selected from the group consisting of: an amine claim 1 , an amino acid claim 1 , an amino sulfonate claim 1 , a hydrophilic multifunctional polymer claim 1 , a hydrophobic multifunctional polymer claim 1 , an α-dicarbonyl claim 1 , a hydrazide claim 1 , an N claim 1 ,N-disuccinimidyl carbonate claim 1 , a carbodiimide claim 1 , a 2-chloro-1-methylpyridinium iodide (CMPI) claim 1 , an antibiotic claim 1 , a cell recruiting agent claim 1 , a hemocompatibility agent claim 1 , an anti-inflammatory agent claim 1 , an anti-proliferative agent claim 1 , an immunogenic suppressing agent claim 1 , a reducing agent claim 1 , and a mono- claim 1 , di- or polyepoxy alkane.3. The method of claim 2 , wherein:the calcification mitigant is an amine; andthe amine is an ethanolamine.4. The method of ...

Methods of preparing personalized blood vessels

The present disclosure relates to methods of preparing personalized blood vessels, useful for transplantation with improved host compatibility and reduced susceptibility to thrombosis. Also provided are personalized blood vessels produced by the methods and use thereof in surgery.

TISSUE REPAIR MEMBRANE ADAPTED FOR ADHESION AND LUBRICATION, AND METHODS FOR PREPARING THE SAME

Provided herein is a tissue repair matrix modified with a hydrogel polymer to provide adhesion and/or lubrication to assist with the use and implantation of the tissue repair membrane, and to facilitate healing and/or avoid or minimize damage to adjacent, e.g., tissues, during or after implantation. 1. A tissue repair membrane comprising a hydrogel polymer coating wherein the hydrogel polymer coating provides one or more of self-adhesion and lubrication to the tissue repair membrane.2. The tissue repair membrane according to wherein the hydrogel polymer is a poly-anionic polymer.3. The tissue repair membrane according to wherein the poly-anionic polymer is selected from the group consisting of hyaluronic acid claim 2 , chondroitin claim 2 , alginate claim 2 , oxidized cellulose claim 2 , heparin claim 2 , dermatan claim 2 , sulfated or otherwise modified versions of the prior polymers and combinations thereof.4. The tissue repair membrane according to wherein the hydrogel polymer is additionally combined with a poly-cationic polymer.5. The tissue repair membrane according to wherein the poly-cationic polymer is selected from the group consisting of chitosan claim 4 , poly-lysine claim 4 , poly-ornithine claim 4 , polyhexamethylene biguanide claim 4 , polyethyleneimine claim 4 , diethylaminoethyl-dextran claim 4 , poly(amidoamine) claim 4 , quaternary ammonium claim 4 , otherwise modified versions of the thereof claim 4 , and combinations thereof.6. The tissue repair membrane according to claim 4 , wherein the hydrogel polymer includes a poly-anionic polymer including hyaluronic acid and is additionally combined with a poly-cationic polymer including chitosan.7. The tissue repair membrane according to wherein the membrane is selected from human tissue and animal tissue claim 1 , and combinations thereof.8. The tissue repair membrane according to wherein the membrane is selected from human cadaver tissue claim 1 , human placental tissue claim 1 , porcine tissue claim ...

METHOD FOR REPAIR OF LIGAMENT OR TENDON

This invention relates to a method for repair of a ligament and/or tendon in a patient comprising applying a patch to said ligament or tendon, wherein the patch is flexible, and bio-compatible and comprises a support layer and a matrix layer. 1. A method for repair of a ligament or tendon in a subject comprising:applying a patch to said ligament or tendon, wherein a support layer comprising collagen, and', 'a matrix layer comprising collagen and hyaluronic acid., 'the patch is flexible and bio-compatible and comprises2. The method of claim 1 , wherein the support layer is a collagen sheet layer.3. The method of claim 1 , wherein the support layer comprises porcine claim 1 , bovine claim 1 , or equine pericardial membrane or porcine split skin.4. The method of claim 1 , wherein the support layer is cell porous.5. The method of claim 1 , wherein the support layer comprises a dried porcine split skin layer.6. The method of claim 1 , wherein the matrix layer comprises a porous collagenous layer.7. The method of claim 6 , wherein the matrix layer comprises a collagen fiber matrix.8. The method of claim 1 , wherein the collagen of the matrix layer comprises collagen of porcine claim 1 , equine claim 1 , bovine or vegetal origin.9. The method of claim 1 , wherein the hyaluronic acid of the matrix layer comprises natural claim 1 , non-human hyaluronic acid.10. The method of claim 9 , wherein the natural claim 9 , non-human hyaluronic acid of the matrix layer comprises natural claim 9 , non-human hyaluronic acid from a bacterial fermentation source.11. The method of claim 1 , wherein the matrix layer hyaluronic acid comprises hyaluronic acid in a form selected from fibers claim 1 , powder claim 1 , gel or cream suspension.12. The method of claim 1 , wherein the matrix layer is a porous collagenous composite pad interspersed with collagen fibers having vacant spaces therebetween and natural hyaluronic acid dispersed into the vacant spaces of the collagen fibers.13. The method ...

Method for Enzymatic Treatment of Tissue Products

Methods for treating tissue matrices and tissue matrices produced according to the methods are provided. The methods can include treating a tissue matrix with a proteolytic enzyme to produce a desired pliability of the tissue matrix. 1. A method for treating a tissue matrix , comprising:selecting a collagen-containing tissue matrix; andcontacting the tissue matrix with a proteolytic enzyme under conditions sufficient to produce a desired level of pliability in the tissue matrix.2. The method of claim 1 , wherein the tissue matrix is an acellular tissue matrix.3. The method of claim 1 , wherein the tissue matrix comprises a dermal tissue matrix.4. The method of claim 1 , wherein the tissue is selected from fascia claim 1 , pericardial tissue claim 1 , dura claim 1 , umbilical cord tissue claim 1 , placental tissue claim 1 , cardiac valve tissue claim 1 , ligament tissue claim 1 , tendon tissue claim 1 , arterial tissue claim 1 , venous tissue claim 1 , neural connective tissue claim 1 , urinary bladder tissue claim 1 , ureter tissue claim 1 , and intestinal tissue.5. The method of claim 1 , wherein the enzyme is bromelain.6. The method of claim 1 , wherein the enzyme is selected from bromelain claim 1 , papain claim 1 , ficin claim 1 , actinidin claim 1 , or combinations thereof.7. The method of claim 1 , wherein the tissue matrix is contacted with the proteolytic enzyme under conditions that do not produce an undesirable change in at least one of tensile strength claim 1 , tear strength claim 1 , suture strength claim 1 , creep resistance claim 1 , burst strength claim 1 , thermal transition temperature claim 1 , or combinations thereof.8. The method of claim 1 , wherein the tissue matrix is contacted with the proteolytic enzyme under conditions that increase the porosity of the tissue matrix.9. The method of claim 1 , wherein the tissue matrix is contacted with the proteolytic enzyme under conditions that do not cause a statistically significant reduction in ...

EXTRACELLULAR MATRIX FOR THE TREATMENT OF INTESTINAL DISEASE AND METHODS THEREOF

A matrix, including epithelial basement membrane, for inducing repair of mammalian tissue defects and in vitro cell propagation derived from epithelial tissues of a warm-blooded vertebrate. 1. A method for making a devitalized material for tissue repair , comprising:extracting epithelial cells from an epithelial tissue by soaking said epithelial tissue in a detergent solution for a period of time sufficient to remove said epithelial cells and epithelial cellular elements from the epithelial basement membrane.2. The method of wherein said period of time is at least 5 minutes.3. The method of wherein said epithelial tissue is urinary bladder.4. The method of wherein said epithelial tissue is intestine.4. The method of wherein said epithelial tissue is skin.6. The method of wherein said epithelial tissue is esophagus.7. The method of wherein said detergent is a non-ionic detergent.8. The method of wherein said non-ionic detergent is polyethylene glycol tert-octylphenyl ether (Triton™ X-100).9. The method of wherein said Polyethylene glycol tert-octylphenyl ether is used at concentrations ranging from about 0.025 to about 1%.10. The method of further comprising rinsing in hypertonic saline.11. The method of further comprising rinsing in peracetic acid.12. The method of further comprising rinsing in sterile water.13. The method of further comprising removing an abluminal portion of the tunica propria claim 1 , and the submucosa claim 1 , tunica muscularis claim 1 , serosa and adventitia by mechanical abrasion.14. The method of further comprising removing said abluminal portions of the tunica propia and the submucosa claim 13 , tunia muscularis claim 13 , serosa and adventitia by combining enzymatic treatment with said mechanical abrasion. This application is a continuation of co-pending U.S. patent application Ser. No. 14/926,132, filed Oct. 29, 2015, which is a continuation of U.S. patent application Ser. No. 14/508,453, filed Oct. 7, 2014, now granted U.S. Pat. No. 9, ...

Compositions and Methods for Treatment of Cardiovascular Disorders

Methods for treating cardiovascular disorders that include administration of an ECM based composition to damaged cardiovascular tissue in conjunction with a treatment remedy, such as transmyocardial revascularization (TMR), which induces enhanced bioremodeling of the damaged cardiovascular tissue and regeneration of new cardiovascular tissue and associated structures with site-specific structural and functional properties. 1. A method for treating damaged cardiovascular tissue of a subject , the method comprising the steps of:providing a mixed gel extracellular matrix (ECM) composition, said ECM composition comprising acellular ECM from a mammalian tissue source,said acellular ECM adapted to induce a first level of stem cell migration, stern cell proliferation, angiogenesis, and bioremodeling of said damaged cardiovascular tissue, and regeneration of new cardiovascular tissue, when said acellular ECM is delivered to said damaged cardiovascular tissue;providing a transmyocardial revascularization (TMR) device, said TMR device adapted to generate laser energy and transmit said laser energy to a target cardiovascular tissue region disposed proximate said damaged cardiovascular tissue, wherein an inciting event is induced in said target cardiovascular tissue region and a TMR energy impact region is formed proximate said damaged cardiovascular tissue, whereby a second level of stem cell migration, stem cell proliferation and angiogenesis of said damaged cardiovascular tissue is induced; anddelivering said ECM composition to said damaged cardiovascular tissue in conjunction with directing first laser energy to a first target cardiovascular tissue region disposed proximate said damaged cardiovascular tissue with said TMR device, wherein a first inciting event is induced in said target cardiovascular tissue region and a first TMR energy impact region is formed proximate said damaged cardiovascular tissue,said ECM composition and first inciting event jointly inducing a third ...

FIXED-SHAPE TISSUE MATRIX AND RELATED METHODS

The present disclosure provides tissue products produced from a combination of three-dimensional biologic scaffolds and acellular tissue matrices. The tissue products may include features for suture or fixation reinforcement. The tissue products may harness various properties of different acellular tissue matrices and different three-dimensional biologic scaffolds to provide improved composite structures with desired mechanical and/or biologic properties. 1. A tissue product comprising:a plurality of acellular tissue matrix particles formed into a three-dimensional shape, wherein the three-dimensional shape is in the shape of an anatomic structure, and wherein the three-dimensional shape is substantially fixed by irradiation.2. The tissue product of claim 1 , wherein the acellular tissue matrix particles comprise acellular dermal matrix.3. The tissue product of claim 1 , wherein the acellular tissue matrix particles comprise acellular adipose matrix.4. The tissue product of claim 1 , wherein the acellular tissue matrix particles comprise porcine-derived tissue matrix.5. The tissue product of claim 1 , wherein the acellular tissue matrix particles comprise human-derived tissue matrix.6. The tissue product of claim 1 , wherein the three-dimensional shape is formed by molding claim 1 , electron beam exposure claim 1 , dehydrothermal therapy claim 1 , or a combination thereof.7. The tissue product of claim 1 , wherein the three-dimensional shape includes at least a first shape and a second shape.8. The tissue product of claim 1 , wherein the anatomical structure comprises a nipple.9. The tissue product of claim 1 , wherein the anatomic structure replicates an anatomic structure of a specific individual.10. A method of forming a tissue product with a fixed three-dimensional shape comprising:forming a plurality of acellular tissue matrix particles to a mold with a three-dimensional shape, wherein the three-dimensional shape is in the shape of an anatomic structure;shaping ...

METHOD OF MANUFACTURING PARTICULATE TISSUE PRODUCTS

The present disclosure relates to a method for manufacturing particulate tissue products. The methods can include cutting a sheet of tissue matrix into elongated strips. In various embodiments, the method for manufacturing particulate tissue product further includes bundling the strips and slicing the bundle into particulate tissue product. The particulates may have improved properties, such as a uniform size distribution. 1. A method of manufacturing particulate tissue products comprising:selecting a tissue matrix;cutting a tissue matrix into elongated tissue matrices;combining the one or more elongated tissue matrices into a group of elongated tissue matrices; andcutting the group of elongated tissue matrices to produce a group of particulate tissue products.2. The method of claim 1 , wherein the elongated tissue matrices each have an approximately uniform cross sectional area.3. The method of claim 1 , further comprising treating one or more elongated tissue matrices to alter the physical or chemical properties of the elongated tissue matrices.4. The method of claim 1 , wherein the group of elongated tissue matrices comprises a bundle of elongated tissue matrices.5. The method of claim 1 , wherein the group of elongated tissue matrices is rigidified.6. The method of claim 5 , wherein the group of elongated tissue matrices is rigidified by fixing the group of elongated tissue matrices in embedding medium.7. The method of claim 1 , wherein cutting the group of elongated tissue matrices to produce particulate tissue products comprises cutting along a plane approximately perpendicular to the a axis of the group of elongated tissue matrices8. The method of claim 1 , wherein a microtome is used to cut the group of elongated tissue matrices.9. The method of claim 8 , wherein the microtome used to cut the group of elongated tissue matrices comprises a cryostat microtome.10. The method of claim 1 , wherein the group of particulate tissue products has a narrow size ...

CARDIOSPHERE-DERIVED CELL SHEET AND METHODS OF MAKING AND USING THE SAME

A method of making a cell sheet comprising secondary spheroids, including (a) obtaining cardiosphere-derived cells; (b) cultivating the cardiosphere-derived cells for a first period of time in a first media comprising at least one of an ascorbic acid and an analog thereof, to form secondary spheroids; (c) transferring an amount of the spheroids formed in step (b) into a mold; (d) culturing the secondary spheroids for a second period of time in a second media comprising at least one of the ascorbic acid and an analog thereof, wherein the at least one of the ascorbic acid and an analog thereof is present in an amount effective to promote a formation of an extracellular matrix; and (e) culturing a product obtained in step (d) for a third period of time, in the absence of the at least one of the ascorbic acid and an analog thereof. 1. A method of making a cell sheet comprising secondary spheroids , comprising:(f) obtaining cardiosphere-derived cells;(g) cultivating the cardiosphere-derived cells for a first period of time in a first media comprising at least one of an ascorbic acid and an analog thereof, to form secondary spheroids;(h) transferring an amount of the spheroids formed in step (b) into a mold;(i) culturing the secondary spheroids for a second period of time in a second media comprising at least one of the ascorbic acid and an analog thereof, wherein the at least one of the ascorbic acid and an analog thereof is present in an amount effective to promote a formation of an extracellular matrix; and(j) culturing a product obtained in step (d) for a third period of time, in the absence of the at least one of the ascorbic acid and an analog thereof.2. The method of claim 1 , wherein the first period of time is about 24 hours.3. The method of claim 1 , wherein the second period of time is about 3 days.4. The method of claim 1 , wherein the third period of time is about 4 days.5. The method of claim 1 , wherein a total of the second and third periods of times is ...

Method for preparing biological tissue for surgical implantation

The present invention relates to a method for treating biological tissue and a biological tissue obtained by the treatment method, and specifically to a method for treating biological tissue so as to suppress the calcification, risk of biofilm adherent over pericardium and strength reduction of the tissue due to treatment. The invention is also directed to bioprosthesis and transcatheter heart valves containing the biological tissue.

BREAST TREATMENT DEVICE

The present disclosure provides devices and methods for treating breasts. The devices can include an acellular tissue matrix having a predefined shape that allows for complete or enhanced coverage of an anterior portion of a breast implant or tissue expander or to support an implant and/or surrounding tissues. 1. A breast treatment device , comprising:a sheet of acellular tissue matrix, wherein the sheet of acellular tissue matrix comprises a flexible sheet with a top surface and a bottom surface, wherein the sheet has an upper curved border having a first degree of curvature and a lower curved border having a second degree of curvature, wherein the lower curved border is shaped and sized to conform to a desired shape of a lower margin of a breast, and wherein the upper curved border is sized and shaped such that the flexible sheet of acellular tissue matrix can cover substantially all of the anterior surface of a breast implant or tissue expander when implanted in a breast.2. The device of claim 1 , wherein the sheet of acellular tissue matrix comprises a dermal tissue matrix.3. The device of claim 1 , wherein the acellular tissue matrix is a porcine tissue matrix.4. The device of claim 1 , wherein the acellular tissue matrix is a human tissue matrix.5. The device of claim 1 , wherein the device further comprises a breast implant or tissue expander.6. A breast treatment device claim 1 , comprising:a sheet of acellular tissue matrix, wherein the sheet of acellular tissue matrix comprises a flexible sheet with a top surface and a bottom surface, wherein the sheet comprises a lower curved border and an upper curved border, wherein the upper curved border and lower curved border are joined at apices at lateral ends of the device, and the sheet is symmetrically shaped about an axis midway between the apices and parallel to the top and bottom surfaces when lying on a flat surface, wherein the lower border forms a single outward arc shape, and wherein the upper border has ...

MULTI-PORTION REPLACEMENT HEART VALVE PROSTHESIS

A replacement mitral valve prosthesis includes a support structure and a valve body having three flexible leaflets. The support structure preferably includes an internal valve frame and an external sealing frame. The valve frame supports the flexible leaflets. The sealing frame is adapted to conform to the shape of the native mitral valve annulus. The sealing frame may be coupled to an inlet end of the valve frame, an outlet end of the valve frame, or both. A plurality of anchors are coupled to the outlet end of the valve frame. The anchors extend radially outwardly for placement behind native leaflets. The prosthesis preferably includes a skirt disposed along an exterior of the external sealing frame. The prosthesis is collapsible for delivery into the heart via a delivery catheter. The prosthesis is configured to self-expand for deployment in the heart when released from the delivery catheter. 1. A replacement heart valve prosthesis , the prosthesis comprising: [ the first anchoring feature extends radially outwardly from the first lower region; and', 'at least a portion of the first anchoring feature extends towards the first upper region; and, 'a first frame portion comprising a first frame body and a first anchoring feature, the first frame body comprising a first upper region, a first intermediate region, and a first lower region, wherein, when the prosthesis is in an expanded configuration, at least a portion of the second upper region extends radially outwardly from the first upper region;', 'the second lower region is positioned radially between the first anchoring feature and the first frame body; and', 'the second intermediate portion is configured such that, when the prosthesis is deployed within the native heart valve, the second intermediate portion is positioned within a native valve annulus; and, 'a second frame portion positioned radially outward of the first frame body, the second frame portion comprising a second frame body having a second upper ...

PERICARDIAL SEALING MEMBER FOR PROSTHETIC HEART VALVE

In one embodiment, a delivery assembly can comprise an annular frame, a leaflet structure positioned within the frame and secured thereto, and an outer skirt positioned around an outer surface of the frame. The annular frame can comprise an inflow end and an outflow end and can be radially collapsible and expandable between a radially collapsed configuration and a radially expanded configuration. The outer skirt can comprise pericardial tissue having a fibrous parietal layer defining a first surface of the outer skirt and a serous parietal layer defining a second surface of the outer skirt. The outer skirt can be positioned such that the first surface is facing away from the frame and the second surface is facing towards the frame. 1. An implantable prosthetic valve comprising:an annular frame comprising an inflow end and an outflow end and being radially collapsible and expandable between a radially collapsed configuration and a radially expanded configuration;a leaflet structure positioned within the frame and secured thereto; andan outer skirt positioned around an outer surface of the frame, wherein the outer skirt comprises pericardial tissue having a fibrous parietal layer defining a first surface of the outer skirt and a serous parietal layer defining a second surface of the outer skirt, and wherein the outer skirt is positioned such that the first surface is facing away from the frame and the second surface is facing towards the frame.2. The prosthetic valve of claim 1 , wherein the outer skirt comprises bovine pericardial tissue.3. The prosthetic valve of claim 1 , wherein the outer skirt is laser milled to reduce its thickness.4. The prosthetic valve of claim 1 , wherein the thickness of the outer skirt is between 50 μm and 150 μm.5. The prosthetic valve of claim 1 , wherein the outer skirt comprises a plurality of openings or slits.6. The prosthetic valve of claim 5 , wherein at least one of the openings or slits is elongated in an axial direction.7. The ...

ANTI-THROMBOGENIC GRAFTS

The present invention provides anti-thrombogenic compositions, including anti-thrombogenic vascular grafts. In certain embodiments, the compositions comprise decellularized tissue coated with an anti-thrombogenic coating. The present invention also provides methods of preparing anti-thrombogenic compositions and methods of treatment comprising implanting the anti-thrombogenic compositions into a subject in need thereof. 1. A composition comprising a substrate having at least one surface coated with an anti-thrombogenic coating.2. The composition of claim 1 , wherein the anti-thrombogenic coating comprises a first layer comprising a hydrogel.3. The composition of claim 2 , wherein the first layer comprises hyaluronic acid.4. The composition of claim 3 , wherein the hyaluronic acid is thiol-modified hyaluronic acid.5. The composition of claim 2 , wherein the first layer is crosslinked to the at least one surface of the substrate.6. The composition of claim 2 , wherein the anti-thrombogenic coating further comprises a second layer comprising an anti-coagulant claim 2 , wherein the second layer is crosslinked to the first layer.7. The composition of claim 6 , wherein the second layer comprises heparin.8. The composition of claim 1 , wherein the substrate is decellularized tissue.9. The composition of claim 8 , wherein the decellularized tissue is a decellularized blood vessel having a luminal surface claim 8 , and wherein the anti-thrombogenic coating is coated on the luminal surface of the decellularized blood vessel.10. A method of preparing a graft coated with an anti-thrombogenic coating claim 8 , comprising the steps of:providing a substrate having at least one surface; and applying a first crosslinking solution to the surface; and', 'applying a hydrogel solution to the surface, thereby providing a first layer on the surface of the substrate., 'coating the at least one surface with an anti-thrombogenic coating, wherein said step of coating comprises11. The method ...

BIOENGINEERED ALLOGENEIC BLOOD VESSEL

The present invention relates to methods for recellurization of blood vessels. This method is particularly useful for producing an allogeneic vein, wherein a donor vein is decellularized and then recellularized using whole blood or bone marrow stem cells. The allogeneic veins produced by the methods disclosed herein are particularly advantageous for implantation or transplantation into patients with vascular diseases. 1. A method of recellularizing a blood vessel comprising introducing endothelial cells and smooth muscle cells and/or progenitor cells for endothelial and smooth muscle cells to the lumen of a decellularized blood vessel and culturing said population of cells on the decellularized blood vessel , thereby recellularizing the blood vessel.2. The method of claim 1 , wherein said cells are from peripheral or whole blood or from bone marrow.3. The method of claim 1 , wherein said cells are introduced as whole blood.4. The method of claim 1 , wherein said cells are expanded and differentiated into endothelial cells and smooth muscle cells in vitro prior to introducing the endothelial cells and the smooth muscle cells to the decellularized blood vessel.5. The method of claim 1 , wherein said introducing the cells to the decellularized blood vessel is by injection or perfusion.6. The method of claim 1 , wherein said culturing comprises perfusion of endothelial cell medium and/or smooth muscle cell medium.7. The method of claim 6 , wherein said perfusion of said endothelial cell medium and said smooth muscle cell medium are administered in alternation.8. The method of claim 7 , wherein said administration in alternation is repeated at least twice.9. The method of claim 1 , wherein said culturing the cells on the decellularized blood vessel results in proliferation and/or differentiation of the cells to endothelial cells and smooth muscle cells.10. The method of claim 9 , wherein said endothelial cells line the inner lining or the lumen of the decellularized ...

Tilapia Dried Tissue – Revi-Aid

The invention is employing the application of tilapia skin that has been processed and preserved in a dried tissue stage. To reach dried tissue stage, the fish skin is required to undergo treatment of Gludehyde and Glycerin solutions that is performed inside the clean room. The skin in new dried stage is then integrated with an adhesive strip and sterile gauze inside the clean room to create a new type of Ready-To-Use bandage that can be utilized as medical dressing for skin injuries, namely Revi-Aid. 1. A new type of bandage called Revi-Aid™ contains sterile gauze and dried tissue fish skin. The dried tissue fish skin , specifically Tilapia , naturally contains collagen to accelerate the healing process of skin injuries or flesh wounds.2. This type of bandage called Revi-Aid™ is created to intentionally cover the open wound for the burned patients; therefore , the size of Revi-Aid™ will be larger comparing to traditional medical dressing bandages.3. The adhesive strip and the non-stick plastic coating paper , along with the sterile gauze layer , will protect the dried tissue fish skin from exposure to air. That will preserve the sterile stage and dried stage for the fish skin until it is removed and ready-to-use when applying the fish skin surface to the open wounds or skin injuries.The purpose of the Revi-Aid™ will minimize the risk of open wounds or skin injuries from exposure to contaminated air, which may cause infections. The skin of the tilapia is harvested after the fish is mutilated. The skin is washed and cleaned with running cold water to remove all impurities such as excess muscles, blood, and extra fiber. The fish skin is then transferred to the Clean Room to process using the following method:Step 1: Place the skin in a container and wash with sterile saline.Step 2: Place the skin in a sterile container containing 0.25% Gludehyde solution.Step 3: Place the skin in a container with 20% alcohol solution for 24 hours to sterilize.Step 4: Wash the skin ...

Dura mater biological patch and preparation method thereof

The invention of biological dura mater patch and a preparation method thereof. Raw material of patch does not come from commercial meat animals, but from breeding animals, such as SIS patch of the sow, has natural good mechanical properties; the method uses plant-derived reagents in the decellularization process, no damage to ECM natural structural base, and retain more active ingredients, has a better ability to induce tissue repair and growth; neither uses a cross-linking agent to enhance mechanical properties, nor synthetic detergents used to remove cells; chemical residues and their toxicity are avoided, while more effective ingredients in ECM, especially GAGs be retained. The patch has soft texture and good toughness, easy to sew tightly, and prevent cerebrospinal fluid leakage; and degradation rate is basically synchronized with the growth of the new dura mater, which is more conducive to repair and regeneration of dura mater. 1. A biological patch for repairing dura mater , wherein the patch contains decellularized connective tissue of breeding stock , the breeding stock is specifically adult , reproducible stock , kept for at least one year , excluding young reserve breeding stock , as contrasted to commercial meat stock.2. The patch of claim 1 , wherein the decellularizing agent is mainly composed of saponin.3. The patch of claim 1 , wherein the breeding stock includes sow claim 1 , cow claim 1 , ewe claim 1 , and mare.4. The patch of claim 1 , wherein the connective tissue is one of claim 1 , or a combination of any of: the submucosa of the small intestine claim 1 , the submucosa of the bladder claim 1 , the submucosa of the stomach claim 1 , the dermal matrix claim 1 , the pericardium claim 1 , the meninges claim 1 , the amniotic membrane claim 1 , the visceral membrane claim 1 , and the peritoneum.5. The patch according to claim 1 , wherein the connective tissue of the breeding stock is the submucosa of the small intestine of the sow.6. A method for ...

SURGICAL METHODS OF REPLACING PROSTHETIC HEART VALVES

A two-stage or component-based valve prosthesis that can be quickly and easily implanted during a surgical procedure is provided. The prosthetic valve comprises a support structure that is deployed at a treatment site. The prosthetic valve further comprises a valve member configured to be quickly connected to the support structure. The support structure may take the form of a stent that is expanded at the site of a native valve. If desired, the native leaflets may remain and the stent may be used to hold the native valve open. In this case, the stent may be balloon expandable and configured to resist the powerful recoil force of the native leaflets. The support structure is provided with a coupling means for attachment to the valve member, thereby fixing the position of the valve member in the body. The valve member may be a non-expandable type, or may be expandable from a compressed state to an expanded state. The system is particularly suited for rapid deployment of heart valves in a conventional open-heart surgical environment. 1providing an expandable anchoring member having a generally tubular expandable body, the anchoring member being adapted to be constricted to a collapsed state for advancement through the vasculature and adapted to be enlarged to an expanded state sized for contacting the heart valve annulus;providing a prosthetic valve member sized to be supported within the anchoring member, the prosthetic valve member including a metallic support structure and three leaflets configured to permit flow in an outflow direction through the prosthetic valve member;creating a direct access pathway through an apex of the heart;delivering the anchoring member to a position within the heart valve annulus while the anchoring member is in the collapsed state; andenlarging the anchoring member to the expanded state and into contact with the heart valve annulus;wherein the prosthetic valve member is supported within the anchoring member during use and the leaflets ...

METHODS OF IMPLANTING A DRY BIOPROSTHETIC VALVED CONDUIT

A valved conduit including a bioprosthetic valve, such as a heart valve, and a tubular conduit sealed with a bioresorbable material. The bioprosthetic heart valve includes prosthetic tissue that has been treated such that the tissue may be stored dry for extended periods without degradation of functionality of the valve. The bioprosthetic heart valve may have separate bovine pericardial leaflets or a whole porcine valve. The sealed conduit includes a tubular matrix impregnated with a bioresorbable medium such as gelatin or collagen. The valved conduit is stored dry in packaging in which a desiccant pouch is supplied having a capacity for absorbing moisture within the packaging limited to avoid drying the bioprosthetic tissue out beyond a point where its ability to function in the bioprosthetic heart valve is compromised. The heart valve may be sewn within the sealed conduit or coupled thereto with a snap-fit connection. 1. A method of preparing and delivering a valved conduit , comprising:removing a pre-assembled valved conduit from a dry package in which the valved conduit is stored without a preserving solution, the valved conduit including a bioprosthetic heart valve coupled to a conduit, the heart valve having leaflets of bioprosthetic tissue and the conduit being sealed with a bioresorbable medium; anddelivering and securing the valved conduit to an implantation site.2. The method of claim 1 , wherein the conduit is secured to the bioprosthetic valve using sutures.3. The method of claim 2 , wherein the heart valve has a suture-permeable sewing ring surrounding an inflow end thereof claim 2 , wherein an inlet end of the conduit is secured to the sewing ring with sutures.4. The method of claim 3 , wherein the heart valve has commissure posts between which the leaflets are supported and a sewing ring claim 3 , and the heart valve couples to the conduit with the commissure posts inside the conduit and the sewing ring outside the conduit.5. The method of claim 1 , ...

TISSUE PRODUCTS WITH ACTIVE AGENTS AND METHODS OF PRODUCTION

The present disclosure relates to methods for producing tissue matrix products with active agents to achieve localized distribution and controlled active agent release. The method can include inserting a carrier element comprising a biodegradable material and active agent into surface features of a tissue matrix product. Also provided are tissue matrix products made using the disclosed methods. 1. A tissue product prepared by a process , comprising:selecting an acellular tissue matrix;positioning at least one microneedle array at a desired depth within the acellular tissue matrix; andinjecting an active agent into the acellular tissue matrix using the at least one microneedle array at a first position on the tissue matrix while controlling the injection rate and retraction rate of the microneedle array to produce a desired distribution of the active agent through a thickness of the acellular tissue matrix.2. The tissue product of claim 1 , wherein the process further comprises positioning the at least one microneedle array at a second position that is spatially distinct from the first position on the acellular tissue matrix and injecting additional active agent at the second position.3. The tissue product of claim 2 , further comprising repeatedly positioning the at least one microneedle array at least one additional position that is spatially distinct from previous injection positions on the acellular tissue matrix and injecting additional active agent.4. The tissue product of claim 1 , wherein the active agent includes antimicrobial agents claim 1 , comprising at least one of an antibacterial claim 1 , an antifungal claim 1 , an antiviral claim 1 , or an antiprotozoal agent.5. The tissue product of claim 4 , wherein the antimicrobial agent comprises chlorhexidine digluconate.6. The tissue product of claim 1 , wherein the process further comprises sterilizing the acellular tissue matrix.7. A tissue matrix product comprising:a tissue matrix;tissue matrix surface ...

LOW GRADIENT PROSTHETIC HEART VALVES

A low pressure gradient prosthetic heart valve for implant in a human. The valve includes a support frame with undulating inflow cusps and outflow commissure posts to which flexible leaflets attach and coapt in a flow area. The commissure posts angle outward in a neutral state to widen the outflow orifice area. Also, the leaflets are designed to fit within the support frame and expand outward in a valve open state without creating a shelf or belly that would restrict flow. 1. A low pressure gradient prosthetic heart valve , comprising:a support frame including a leaflet attachment edge with an undulating shape defined by alternating arcuate inflow cusp regions and on an inflow end and arcuate outflow commissure posts on an outflow end, the support frame, in a relaxed state, circumscribing a flow volume having a central axis, the flow volume having a maximum flow orifice area perpendicular to the central axis limited by the inflow end of the support frame; anda plurality of flexible bovine pericardial leaflets attached to the support frame and extending inward toward the axis, each leaflet having an arcuate cusp edge with no straight portions opposite a free edge and opposed attachment tabs therebetween, wherein the cusp edge conforms to a corresponding support frame cusp region and attaches therealong between adjacent commissure posts, and a free edge that coapts with the free edges of the other leaflets to provide one way flow through the valve, wherein the cusp edge is defined by a complex curve of multiple radii;wherein when the valve opens the free edges of the leaflets move outward toward the support frame from fluid flow in an outflow direction and corresponding fluid pressures, and wherein each leaflet has a size and is attached to the corresponding support frame cusp region such that when the valve opens the leaflets spread outward to provide an outflow orifice area that is no less than the maximum flow orifice area.2. The heart valve of claim 1 , wherein ...

METHODS OF PREPARING AND DELIVERING A DRY BIOPROSTHETIC VALVED CONDUIT

A valved conduit including a bioprosthetic valve, such as a heart valve, and a tubular conduit sealed with a bioresorbable material. The bioprosthetic heart valve includes prosthetic tissue that has been treated such that the tissue may be stored dry for extended periods without degradation of functionality of the valve. The bioprosthetic heart valve may have separate bovine pericardial leaflets or a whole porcine valve. The sealed conduit includes a tubular matrix impregnated with a bioresorbable medium such as gelatin or collagen. The valved conduit is stored dry in packaging in which a desiccant pouch is supplied having a capacity for absorbing moisture within the packaging limited to avoid drying the bioprosthetic tissue out beyond a point where its ability to function in the bioprosthetic heart valve is compromised. The heart valve may be sewn within the sealed conduit or coupled thereto with a snap-fit connection. 1. A method of preparing and delivering a valved conduit , comprising:procuring a pre-assembled valved conduit including a prosthetic heart valve having bioprosthetic tissue that has been treated such that the tissue may be stored dry for extended periods without degradation of functionality of the valve, the valve being coupled to a conduit sealed with a bioresorbable medium so as to provide the valved conduit and stored in a dry package including at least one sterile container in which the valved conduit is stored without a preserving solution;opening the dry package and removing the valved conduit; anddelivering the valved conduit to an implantation site.2. The method of claim 1 , wherein the conduit is secured to the bioprosthetic valve using sutures.3. The method of claim 1 , wherein the bioprosthetic valve couples within the conduit such that the conduit extends on both ends of the valve to provide both inflow and outflow extensions.4. The method of claim 1 , wherein the bioprosthetic valve is a heart valve and includes bovine pericardial ...

METHOD FOR PROTECTING SKELETONIZED BLOOD VESSELS

Skeletonized blood vessels for use as vascular grafts are protected from biomechanical injury and/or certain cellular and extracellular changes by application of a biocompatible hydrogel to the vessel exterior. The hydrogel may be applied to the vessel graft before or after harvesting from a donor patient. 1. A method for protecting a skeletonized blood vessel , comprising forming a coating on at least a portion of an outer surface of the blood vessel , wherein the coating comprises a biocompatible hydrogel.2. The method according to claim 1 , wherein the blood vessel is a vein.3. The method according to claim 1 , wherein the blood vessel is an artery.4. The method according to claim 1 , wherein the blood vessel is selected from the group consisting of aortas claim 1 , carotid arteries claim 1 , coronary arteries claim 1 , internal mammary arteries claim 1 , internal thoracic arteries claim 1 , radial arteries claim 1 , femoral arteries claim 1 , gastroepiploic arteries claim 1 , popliteal arteries claim 1 , and saphenous veins.5. The method according to claim 4 , wherein the blood vessel is an internal thoracic artery.6. The method according to claim 4 , wherein the blood vessel is a saphenous vein.7. The method according to claim 4 , wherein the blood vessel is a radial artery.8. The method according to claim 4 , wherein the blood vessel is a gastroepiploic artery.9. The method according to any one of - claim 4 , wherein the blood skeletonized vessel is harvested from a donor claim 4 , further comprising depositing the coating on the outer surface of the blood vessel in the donor before harvesting.10. The method according to claim 9 , wherein the donor is a patient who receives the protected skeletonized vessel.11. The method according to any one of - claim 9 , further comprising delivering to the outer surface a composition comprising two or more hydrogel precursor reactants claim 9 , whereby the two or more hydrogel precursor reactants react and form the ...

REGENERATED HAIR FOLLICLE PRIMORDIUM AGGREGATION MANUFACTURING METHOD, HAIR FOLLICLE TISSUE-CONTAINING SHEET, AND METHOD FOR MANUFACTURING HAIR FOLLICLE TISSUE-CONTAINING SHEET

The present invention provides a method for manufacturing a regular and high-density regenerated hair follicle primordium aggregation similar to the hair follicle tissue of a mammal in a simple manner. A regenerated hair follicle primordium aggregation manufacturing method of the present invention includes a step of forming hair follicle primordia by inoculating a microwell plate, which includes regularly arranged microwell portions, with mesenchymal cells and epithelial cells and culturing a mixture of the cells while supplying oxygen thereto. 1. A regenerated hair follicle primordium aggregation manufacturing method , comprising:a step of inoculating a microwell plate, which has regularly arranged microwell portions, with mesenchymal cells and epithelial cells and culturing a mixture of the cells while supplying oxygen thereto from all surfaces of the microwell plate so as to form hair follicle primordia in the microwell portions,wherein the microwell plate is formed of an oxygen permeable material.2. (canceled)3. A hair follicle tissue-containing sheet , comprising:hair follicle primordia including mesenchymal cells and epithelial cells; anda biocompatible hydrogel,wherein the hair follicle primordia are regularly arranged on the biocompatible hydrogel approximately at the same density as the density of pores of a mammal.4. The hair follicle tissue-containing sheet according to claim 3 , wherein the hair follicle primordia are differentiated and form hair follicles.5. The hair follicle tissue-containing sheet according to claim 3 , wherein the biocompatible hydrogel is an extracellular matrix component which gelates.6. The hair follicle tissue-containing sheet according to claim 5 , wherein the extracellular matrix component is collagen.7. The hair follicle tissue-containing sheet according to claim 3 , wherein the density of the hair follicle primordia is equal to or higher than 20 primordia/cmand equal to or lower than 500 primordia/cm.8. A method for ...

PROSTHETIC HEART VALVE INCLUDING STENT STRUCTURE AND TISSUE LEAFLETS, AND RELATED METHODS

A method of making a prosthetic heart valve may include providing an annular stent having a plurality of annularly spaced commissure portions having tips, covering each of the tips with a first fabric cover, covering the first fabric covers and the remainder of the stent with a second fabric cover, covering the second fabric cover with a first tissue membrane, and covering the outside of the first tissue membrane with a second tissue membrane, the second tissue membrane forming leaflet portions that extend inwardly between the commissure portions. 1. (canceled)2. A prosthetic heart valve , comprising:an annular stent having an inner side, an outer side, an inflow edge and an outflow edge;a first fabric cover over a portion of the outflow edge, the first fabric cover not extending to a remainder of the annular stent;a second fabric cover that extends over the first fabric cover and over the remainder of the inner side of the annular stent and the outer side of the annular stent;a first tissue membrane covering the second fabric cover; anda second tissue membrane that surrounds the first tissue membrane on the outer side of the stent.3. The prosthetic heart valve as claimed in claim 2 , wherein the stent is made of metal.4. The prosthetic heart valve as claimed in claim 2 , wherein the stent is made of polymer.5. The prosthetic heart valve as claimed in claim 2 , wherein the first tissue membrane comprises mammalian pericardium.6. The prosthetic heart valve as claimed in claim 2 , wherein the second tissue membrane comprises mammalian pericardium.7. The prosthetic heart valve as claimed in claim 2 , further comprising a sewing cuff positioned adjacent the inflow edge of the stent.8. The prosthetic heart valve as claimed in claim 7 , wherein the inflow edge of the stent has a shape claim 7 , and the sewing cuff has a shape corresponding to the shape of the inflow edge of the stent.9. The prosthetic heart valve as claimed in claim 7 , wherein the inflow edge has a ...

Triangular fibrocartilage complex reconstruction techniques

This disclosure is directed to methods for reconstructing an unstable triangular fibrocartilage complex (TFCC). Exemplary methods include preparing, delivering, and fixating a graft within a distal radioulnar joint in a manner that restores the functionality to the TFCC, thereby improving the joint kinematics of the radioulnar joint.

Enzyme-activated collagen and tissue matrices

Devices and methods for treating defects in connective tissue are provided along with methods for making such devices. The devices can include enzyme-activated acellular tissue matrices that facilitate regrowth of the damaged tissue.

TISSUE MODIFICATION DEVICES, SYSTEMS, AND METHODS

A tissue modification apparatus includes at least a first plurality of grippers aligned in a plane adapted to secure a first edge of a patch of tissue. The plurality of grippers are each secured to a first force actuator. The first plurality of grippers are each adapted to pivot relative to the first force actuator about an axis perpendicular to the plane. In some cases, a plurality of grippers are attached to a force actuator by a passive force transfer mechanism. In some cases, individual force actuators are attached by pivoted connections to individual grippers. Methods of treating tissue can secure tensioned tissue to a frame to retain the tension during a treatment (e.g., cross-linking the tissue with a chemical cross-linker). 1. A tissue modification apparatus comprising at least a first plurality of grippers aligned in a plane adapted to secure a first edge of a patch of tissue , the plurality of grippers each being secured to a first force actuator , the first plurality of grippers each being adapted to pivot relative to the first force actuator about an axis perpendicular to the plane.2. The tissue modification apparatus of claim 1 , further comprising a second plurality of grippers aligned in the plane opposite the first plurality of grippers claim 1 , the second plurality of grippers being adapted to secure a second edge of a patch of tissue claim 1 , the second plurality of grippers each being adapted to pivot about an axis perpendicular to the plane claim 1 , the first plurality of grippers being adapted to pull the tissue in a direction opposite the second plurality of grippers such that a patch of tissue secured between the first and second plurality of grippers can be stretched along a first orientation.3. The tissue modification apparatus of claim 2 , wherein the second plurality of grippers are each secured to a second force actuator via pivoted connections such that the first and second force actuators are adapted to pull the first and second ...

Methods and systems for stiffening of tissue for improved processing

Methods and systems for stiffening of tissue are presented to allow improved processing. Solutions including an acid or a base can be contacted with tissue to stiffen one or more components of the tissue. The resulting stiffened tissue can be used in the creation of wound treatment devices.

HYDRATABLE COMPOSITIONS COMPRISING MACROPARTICLES AND METHODS OF MAKING THEM

A uniformly hydrated composition is provided and methods of making the uniformly hydrated composition. The method comprises providing a plurality of lyophilized porous macroparticles in a chamber, the plurality of lyophilized porous macroparticles each having an average diameter from about 0.1 mm to about 10 mm and comprising ceramic material and polymer; and mixing each of the plurality of lyophilized porous macroparticles with a fluid in the chamber to uniformly hydrate each of the plurality of lyophilized porous macroparticles to form a uniformly hydrated composition. Hydratable compositions are also provided. 1. A method of making a uniformly hydrated composition , the method comprising providing a plurality of lyophilized porous macroparticles in a chamber , the plurality of lyophilized porous macroparticles each having an average diameter from about 0.1 mm to about 10 mm and comprising ceramic material and polymer; and mixing each of the plurality of lyophilized porous macroparticles with a fluid in the chamber to uniformly hydrate each of the plurality of lyophilized porous macroparticles to form a uniformly hydrated composition.2. The method of claim 1 , wherein (i) the ratio of fluid to the plurality of lyophilized porous macroparticles is from about 1:1 to about 3:1; or (ii) the ceramic is in an amount from about 50 to about 98 wt. % and the polymer is in an amount from about 2 to about 50 wt. % based on a total weight of each of the lyophilized porous macroparticles.3. The method of claim 1 , wherein the plurality of lyophilized porous macroparticles in the chamber has a packing density to maximize hydration of the plurality of lyophilized porous macroparticles.4. The method of claim 1 , wherein the plurality of lyophilized porous macroparticles has shapes comprising cylinders claim 1 , cubes claim 1 , rods claim 1 , tubes claim 1 , hollow tubes claim 1 , rectangles claim 1 , discs claim 1 , half hemispherical hollow tubes claim 1 , electrospun fibers ...

SINGLE-PASS ENDOSCOPIC VESSEL HARVESTING

An endoscopic harvesting device removes a vessel from a body. The vessel has an anterior side closest to the skin. A sheath extends in a longitudinal direction with a dissector tip for advancing along the vessel substantially along the anterior side to create a flanking tunnel spaced away from the vessel. A ring-shaped blade is mounted to the sheath and is disposed in a plane substantially perpendicular to the longitudinal direction and proximal of the dissector tip. The blade forms a lateral loop to encircle the vessel from the flanking tunnel and to make a vasiform cut including a pedicle around the vessel as the sheath advances. 1. Apparatus for endoscopic harvesting of a vessel from a body , wherein the vessel has an anterior side closest to the skin , comprising:a sheath extending in a longitudinal direction with a dissector tip for advancing along the vessel substantially along the anterior side to create a flanking tunnel spaced away from the vessel; anda ring-shaped blade mounted to the sheath and disposed in a plane substantially perpendicular to the longitudinal direction and proximal of the dissector tip, wherein the blade forms a lateral loop to encircle the vessel from the flanking tunnel and to make a vasiform cut including a pedicle around the vessel as the sheath advances.2. The apparatus of wherein the vessel has a plurality of side branches claim 1 , and wherein the blade has a leading edge that cuts and cauterizes the side branches as the sheath advances.3. The apparatus of wherein the blade comprises an ultrasonic cutter at the leading edge.4. The apparatus of wherein the blade is comprised of a partial ring with an open end of the lateral loop being adapted to be initially inserted around the vessel by rotating the blade to puncture tissue around the vessel and the surrounding pedicle claim 1 , so that the vessel remains unsevered while the vasiform cut is made.5. The apparatus of further comprising an endoscopic lens secured to the sheath for ...

Compositions and methods for cardiac therapy

Provided herein are methods and compositions for cardiac therapy. Such compositions include extracellular-matrix (ECM)-based products that can be used to support tissue repair. The compositions can be used for various purposes. In some cases, they can be introduced into a subject in order to preserve and/or repair damaged heart tissue.

PRE-ASSEMBLED PACKAGED BIOPROSTHETIC VALVE CONDUIT

A valved conduit including a bioprosthetic valve, such as a heart valve, and a tubular conduit sealed with a bioresorbable material. The bioprosthetic heart valve includes prosthetic tissue that has been treated such that the tissue may be stored dry for extended periods without degradation of functionality of the valve. The bioprosthetic heart valve may have separate bovine pericardial leaflets or a whole porcine valve. The sealed conduit includes a tubular matrix impregnated with a bioresorbable medium such as gelatin or collagen. The valved conduit is stored dry in packaging in which a desiccant pouch is supplied having a capacity for absorbing moisture within the packaging limited to avoid drying the bioprosthetic tissue out beyond a point where its ability to function in the bioprosthetic heart valve is compromised. The heart valve may be sewn within the sealed conduit or coupled thereto with a snap-fit connection. 1. A pre-assembled , packaged valved conduit , comprising:a bioprosthetic valve including bioprosthetic tissue, the valve having been treated such that the bioprosthetic tissue has less than 70% water content and may be stored dry for extended periods without degradation of functionality of the valve;a conduit sealed with a bioresorbable medium to which the bioprosthetic valve is coupled so as to provide the valved conduit; anddry packaging for the valved conduit including at least one sterile container in which the valved conduit is stored without a preserving solution.2. The valved conduit of claim 1 , wherein the conduit is secured to the bioprosthetic valve using sutures.3. The valved conduit of claim 1 , wherein the bioprosthetic valve is a heart valve and includes bovine pericardial leaflets claim 1 , and the conduit comprises a tubular matrix impregnated with collagen.4. The valved conduit of claim 1 , wherein the tissue has been cross-linked using glutaraldehyde or other aldehyde containing agents claim 1 , treated with a capping agent claim ...

Tissue repair material derived from fish skin and manufacturing method thereof

A tissue repair material derived from fish skin and manufacturing method thereof is applied to provide the tissue repair material suitable for use as a patch, a cover, a carrier, a scaffold, an implant or a reagent in various tissues. The tissue repair material has collagens to improve the wounded tissue repair, and has particular characters for desired tissue repair application. Furthermore, so far the factors of the terrestrial animal transmitted disease (caused by virus) do not survive on the tissue repair material derived from fish skin.

Device for tendon and ligament treatment

Devices and methods for treating defects in connective tissue are provided along with methods for making such devices. The devices can include acellular arterial tissue matrices that facilitate regrowth of the damaged tissue.

Breast treatment device

The present disclosure provides devices and methods for treating the breast. The devices can include an acellular tissue matrix having a predefined shape. The shape can include a first edge with an S-shaped configuration and a second arcuate-shaped edge. The shape alternatively can include a first concave edge and a second convex edge.